UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

Form 10-K

(Mark One)



ý	ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2013



o	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number: 0-27188

Accelrys, Inc.

(Exact name of registrant as specified in its charter)



Delaware		33-0557266
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)
5005 Wateridge Vista Drive, San Diego, California		92121
(Address of principal executive offices)		(Zip Code)

(858) 799-5000

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:



Title of Each Class		Name of Each Exchange on Which Registered
Common Stock, par value $0.0001 per share		NASDAQ Global Select Market

Securities registered pursuant to Section 12(g) of the Act:

None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ¨ No ý

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ¨ No ý

Note—checking the box above will not relieve any registrant required to file reports pursuant to Section 13 of 15(d) of the Exchange Act from their obligations under those Sections.

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ý No ¨

Indicate by checkmark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ý No ¨

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405 of this chapter) is not contained herein, and will not be contained, to the best of the registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ý

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):



Large accelerated filer	o	Accelerated filer	x
Non-accelerated filer	o	Smaller reporting company	o
(Do not check if smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No ý

The aggregate market value of the voting stock held by non-affiliates of the registrant as of June 30, 2013 was $283.2 million (based upon the June 30, 2013 closing price for shares of the registrant’s common stock as reported by the NASDAQ Global Select Market). Shares of common stock held by each officer, director and holder of 5% or more of the outstanding common stock have been excluded in that such persons may be deemed to be affiliates. This determination of affiliate status is not necessarily a conclusive determination for other purposes.

The number of outstanding shares of the registrant’s common stock, par value $0.0001 per share, as of February 24, 2014 was 55,758,925, net of treasury shares.

DOCUMENTS INCORPORATED BY REFERENCE

Portions of Part II of this Form 10-K and Items 10, 11, 12, 13 and 14 of Part III of this Form 10-K incorporate information by reference from the registrant’s definitive proxy statement filed pursuant to Regulation 14A in connection with the registrant’s 2014 Annual Meeting of Stockholders or an amendment to this Annual Report on Form 10-K to be filed with the Securities and Exchange Commission within 120 days after the close of the fiscal year covered by this annual report.

The Exhibit Index (Item No. 15) lists several documents incorporated by reference.

ACCELRYS, INC.

FORM 10-K—ANNUAL REPORT

For the Fiscal Year Ended December 31, 2013

Table of Contents




PART I
Item 1	Business	3
Item 1A	Risk Factors	15
Item 1B	Unresolved Staff Comments	26
Item 2	Properties	26
Item 3	Legal Proceedings	27
Item 4	Mine Safety Disclosures	29

PART II
Item 5	Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	29
Item 6	Selected Consolidated Financial Data	31
Item 7	Management’s Discussion and Analysis of Financial Condition and Results of Operations	32
Item 7A	Quantitative and Qualitative Disclosures About Market Risk	53
Item 8	Financial Statements and Supplementary Data	54
Item 9	Changes in and Disagreements With Accountants on Accounting and Financial Disclosure	98
Item 9A	Controls and Procedures	98
Item 9B	Other Information	99

PART III
Item 10	Directors, Executive Officers and Corporate Governance	101
Item 11	Executive Compensation	101
Item 12	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	101
Item 13	Certain Relationships and Related Transactions, and Director Independence	101
Item 14	Principal Accountant Fees and Services	101

PART IV
Item 15	Exhibits, Financial Statement Schedules	101
Signatures		107

Forward-Looking Statements

This Annual Report on Form 10-K (this “Report”) contains “forward-looking statements” that involve risks and uncertainties, as well as assumptions that, if they never materialize or prove incorrect, could cause our results to differ materially and adversely from those expressed or implied by such forward-looking statements. These statements are often identified by the use of words such as “expect”, “believe”, “anticipate”, “estimate”, “intend”, “plan” and similar expressions and variations or negatives of these words. These forward-looking statements may include statements addressing our future financial and operating results. We have based these forward-looking statements on our current expectations about future events. Such statements are subject to certain risks and uncertainties including those related to the execution of our strategic plans, the successful release and acceptance of new products, the demand for new and existing products, additional competition, changes in economic conditions and those described in documents we have filed with the Securities and Exchange Commission (the “SEC”), including this Report in “Management's Discussion and Analysis of Financial Condition and Results of Operations” and “Risk Factors” and subsequent reports on Form 10-Q. All forward-looking statements in this document are qualified entirely by the cautionary statements included in this document and such other filings. These forward-looking statements speak only as of the date of this document. We disclaim any undertaking to publicly update or revise any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

Unless the context requires otherwise, in this Report the terms “Accelrys,” the “Company,” “we,” “us” and “our” refer to Accelrys, Inc. and its wholly owned or indirect subsidiaries, and their predecessors.

PART I



Item 1.	Business

Change in Fiscal Year

On August 3, 2010, our board of directors approved a change in our fiscal year end from March 31 to December 31. The fiscal year end change was effective December 31, 2010 and resulted in a nine- month reporting period from April 1, 2010 to December 31, 2010. All references to “years”, unless otherwise noted, refer to the twelve-month fiscal year, which prior to April 1, 2010, ended on March 31, and beginning with January 1, 2011, ends on December 31, of each year.

Overview

We have completed the following acquisitions since 2010:

On July 1, 2010, pursuant to the terms of the Agreement and Plan of Merger and Reorganization, dated April 5, 2010, by and among us, Alto Merger Sub, Inc., our wholly owned subsidiary (“Merger Sub”), and Symyx Technologies, Inc., (“Symyx”),Merger Sub merged with and into Symyx, with Symyx surviving as our wholly owned subsidiary (the “Symyx Merger”). Symyx's operating results are included in our consolidated financial statements and results of operations beginning July 1, 2010.

On May 19, 2011, we completed the acquisition of Contur Software AB (“Contur”), whereby Contur became our wholly owned subsidiary (the “Contur Acquisition”). Contur's operating results are included in our consolidated financial statements and results of operations beginning May 19, 2011.

On December 30, 2011, we completed the acquisition of Velquest Corporation (“Velquest”), whereby VelQuest became our wholly owned subsidiary (the “Velquest Acquisition”). VelQuest's operating results are included in our consolidated financial statements and results of operations beginning December 30, 2011.

On May 17, 2012, we acquired a proprietary web-based Hit Explorer Operating System (“HEOS”) software platform from Scynexis, Inc. The operating results of the HEOS platform are included in our consolidated financial statements and results of operations beginning May 17, 2012.

On October 23, 2012, we completed the acquisition of Aegis Analytical Corporation (“Aegis”), whereby Aegis became our wholly owned subsidiary (the “Aegis Acquisition”). Aegis' operating results are included in our consolidated financial statements and results of operations beginning October 23, 2012.

On January 11, 2013, we completed the acquisition of all of the outstanding shares of Vialis AG (“Vialis”), a joint stock company organized under the laws of Switzerland (the “Vialis Acquisition”). Vialis’ operating results are included in our consolidated financial statements and results of operations beginning January 11, 2013.

On September 3, 2013, we completed the acquisition of all of the outstanding shares of ChemSW, Inc. (“ChemSW”), a California corporation (the “ChemSW Acquisition”). ChemSW’s operating results are included in our consolidated financial statements and results of operations beginning September 3, 2013.

On December 9, 2013, we completed the acquisition of all of the outstanding shares of Qumas Limited (“Qumas”), a company incorporated and registered in Ireland (the “Qumas Acquisition” and together with the Symyx Merger, the Contur Acquisition, the VelQuest Acquisition, the Aegis Acquisition, the acquisition of the HEOS platform, the Vialis Acquisition and the ChemSW Acquisition, the “Acquisitions”). Qumas’ operating results are included in our consolidated financial statements and results of operations beginning December 9, 2013.

Recent Developments

On January 30, 2014, we entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Dassault Systemes Americas Corp., a Delaware corporation (“ DSAC”) and a wholly owned indirect subsidiary of Dassault Systèmes SA, a French corporation with limited liability, and 3DS Acquisition Corp., a Delaware corporation and wholly owned subsidiary of DSAC (“Purchaser”). Pursuant to the terms of the Merger Agreement, on February 13, 2014, Purchaser commenced a tender offer (the “Offer”) to purchase all of the outstanding shares of our common stock at a price per share of $12.50, net to the seller in cash, without interest (such amount, as it may be adjusted from time to time on the terms and subject to the conditions set forth in the Merger Agreement the “Offer Price”), and subject to any required withholding of taxes. The initial expiration date of the Offer is 12:00 midnight, New York City time, on March 13, 2014 (which is the end of the day on March 13, 2014), subject to extension in certain circumstances as required or permitted by the Merger Agreement.

The consummation of the Offer is subject to customary closing conditions, including, among other things, (i) the valid tender of shares of our common stock representing at least a majority of the total outstanding shares of our common stock, calculated on a fully diluted basis, (ii) the expiration or termination of waiting periods and the obtaining of all applicable consents or approvals required under applicable antitrust, competition and trade regulation laws of Germany and Austria and (iii) the conclusion or termination of review by The Committee on Foreign Investment in the United States.

Upon completion of the Offer, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Purchaser will be merged with and into Accelrys, Inc. and Accelrys, Inc. will survive as a wholly owned subsidiary of DSAC (the “Merger”). The Merger Agreement provides that the Merger will be governed by Section 251(h) of the Delaware General Corporation Law (the “DGCL”) and will be effected as soon as practicable following the consummation of the Offer without a vote of our stockholders pursuant to Section 251(h) of the DGCL.

Upon completion of the Merger, each outstanding share of our common stock (other than shares owned by Accelrys, Inc., DSAC or Purchaser or their subsidiaries and shares owned by holders who have validly exercised their appraisal rights under the DGCL) will be canceled and converted into the right to receive an amount in cash equal to the Offer Price, payable to the holder thereof on the terms and subject to the conditions set forth in the Merger Agreement. In addition, upon completion of the Merger, (i) each outstanding option to purchase our common stock, whether vested or unvested, will be canceled, with the holder thereof becoming entitled to receive an amount in cash equal to (a) the excess, if any, of (1) the Offer Price minus (2) the exercise price per share of common stock subject to such option, multiplied by (b) the number of shares of common stock subject to such option, and (ii) each outstanding RSU will be canceled, with the holder thereof becoming entitled to receive an amount in cash equal to the product of (a) the number of shares of our common stock subject to such RSU and (b) the Offer Price.

The Merger Agreement contains customary representations, warranties and covenants, including, among other things, covenants regarding the operation of our business prior to the completion of the Merger and covenants obligating us to use reasonable best efforts to obtain required regulatory approvals. The Merger Agreement also contains customary “no solicitation” provisions restricting our ability to solicit or participate in discussions regarding any third-party proposals relating to alternative transactions, subject to certain exceptions to permit our board of directors to comply with its fiduciary duties, including in connection with our receipt of an unsolicited written proposal relating to an alternative transaction that our board of directors determines is or would reasonably be expected to result in a superior proposal.

The Merger Agreement also includes customary termination provisions in favor of both us and DSAC, and provides that in connection with the termination of the Merger Agreement under certain circumstances, we must pay DSAC a termination fee of $25,000,000, including due to termination of the Merger Agreement by us to accept a superior proposal.

Our Business

As the leading provider of scientific innovation lifecycle management software, we develop and commercialize informatics software products and services for industries and organizations that rely on scientific innovation to differentiate themselves in the marketplace, with a particular emphasis on pharmaceutical, biotechnology, energy, chemicals, food and beverage and consumer packaged goods companies. As the basis of Accelrys’ software and services offerings, the Accelrys Enterprise Platform provides a broad, flexible science-based foundation optimized to integrate the diversity of science, experimental processes and information requirements across the research, development, process scale-up and manufacturing phases of product development. Our software applications for Scientific Platform and Data Management, Modeling and Simulation, Research Informatics, Laboratory Informatics, Enterprise Quality Management, Environmental Health & Safety and Operations Intelligence enable innovators to access, organize, analyze and share data in unprecedented ways, ultimately enhancing innovation, improving productivity, reducing compliance risk, lowering costs, enhancing sustainability and accelerating products from lab to market. Additionally, our software manages and connects scientific innovation processes and

information with other lifecycle systems including Enterprise Resource Planning (ERP) and Product Lifecycle Management (PLM) systems.

Our acquisitions over the past three years have been critical initiatives in increasing the breadth and depth of our product portfolio by extending our offerings beyond research and into development and manufacturing with a view to covering the end-to-end product lifecycle.

The addition of the Contur Electronic Laboratory Notebook (ELN) enabled us to make available to customers an easy-to-deploy, easy-to- use ELN that is deployable as both an on-premises and cloud-based notebook. The addition of the VelQuest suite of products increased our downstream capabilities, extending our solutions into the quality assurance and quality control areas in large pharmaceutical companies. The Aegis Acquisition expanded our portfolio into downstream operations with new solutions supporting Operations Intelligence in enterprise manufacturing. In addition, the Vialis Acquisition has added system integration capabilities that have strengthened our position in the Laboratory Informatics market with added capabilities in the downstream analytical development, quality control and quality assurance and manufacturing areas. The ChemSW Acquisition has enabled us to provide solutions for managing and tracking the source, use and disposal of chemicals along the entire lab-to-plant value chain. The Qumas Acquisition has further extended our informatics portfolio with the addition of proven, mission-critical, end-to-end document and process management compliance solutions.

The acquisition of the web-based HEOS drug research information management and collaboration system brought us a cloud-based offering that enables more efficient and streamlined drug delivery collaborations, particularly with organizations leveraging contract research organizations and other groups for externalized R&D projects. The HEOS system has recently been incorporated into ScienceCloud by Accelrys, a new information management and collaboration workspace in the cloud that advances collaborative drug discovery with a new generation of integrated, SaaS-based applications and social communication capabilities to enhance collaborative drug discovery.

Collectively, our products and services are intended to optimize our customers' lab-to-commercialization value chains, from early research through development to manufacturing. Our software is used by scientists, biologists, chemists, engineers and information technology professionals to design, execute and manage experiments in-silico or in the lab and to aggregate, mine, manage, analyze and interactively report on the data resulting from those experiments. Our solutions enable effective scale-up of development processes, automate the transition from development to manufacturing, manage quality control and quality assurance operations and monitor process and product quality, thereby reducing compliance risk. The ability to integrate and access data from diverse data sources and to make that information accessible throughout the scientific innovation value chain enables our customers to reduce costs and enhance productivity in developing products that meet quality and compliance standards.

Our customers include leaders from a variety of industries, including pharmaceutical, biotechnology, energy, chemicals, food and beverage and consumer packaged goods companies, as well as government and academic entities. We market our software products and services worldwide, principally through our direct sales force, augmented by the use of third-party distributors. We are headquartered in San Diego, California and were incorporated in Delaware in 1993.

Description of Our Markets and Business

Our customers rely on science to innovate in their products and processes, differentiating themselves through scientific innovation. As a result, innovation in the discovery, development and manufacturing of new products; compliance with applicable regulations; rapid, cost-effective commercialization of products; and the ability to protect the intellectual property are all crucial to our customers' success. Therefore, our customers invest considerable resources in technologies like those of Accelrys that help them to effectively design, plan and execute experiments in a repeatable process and in compliance with regulations; leverage the vast amounts of information stored in both corporate databases and public data sources to optimize their processes and accelerate innovation; model, predict and analyze potential outcomes; improve product and process understanding throughout development lifecycles; and access comprehensive, integrated and cross-referenced databases and reference works.

The pharmaceutical and biotechnology industries are a very important part of our business. Our products have been widely adopted within the research functions of businesses in these industries and are gaining increased traction in the development, quality assurance/quality control (“QA/QC”) and manufacturing functions of such businesses. In addition, these markets present challenges due to industry consolidation, market maturity, patent expirations, reduced discovery research activity, increased competition, including competition from open source software, and outsourcing of research to other entities. The other industries we serve, including energy, chemicals, food and beverage, and consumer packaged goods companies, are earlier in the adoption curve for such scientific software products but are increasingly investigating their value, which we view as both a challenge and an opportunity.

Business Strategy

Research and development organizations face several challenges that impact their ability to comply with applicable regulations, protect their intellectual property and rapidly and cost-effectively bring products to market. Scientific data is often found in disparate databases and research, development and manufacturing processes are disconnected, manually intensive, inefficient and repetitive. These challenges have made it difficult for organizations to manage the innovation lifecycle to bring novel products to market faster, more efficiently and more sustainably with reduced compliance risk.

Our strategy is to partner with customers to optimize their scientific innovation lifecycle management from discovery through commercialization. Consequently, we are extending beyond our historically strong presence in research downstream to offer customers an integrated portfolio of software and services addressing the entire product lifecycle. This means moving into new domains, including biology; and expanding our presence outside of the pharmaceutical and biotech industries into other key industries such as energy, chemicals, food and beverage and consumer packaged goods companies. We do this by addressing the core challenges faced by R&D and quality organizations, offering them an open enterprise-scale scientific software platform and a broad portfolio of software applications leveraging our deep domain expertise in chemistry, biology and the materials sciences. We believe the combination of the Accelrys Enterprise Platform with its Component Collections and associated set of applications and services including the Accelrys Pipeline Pilot authoring application and software capabilities in Scientific Platform and Data Management, Modeling and Simulation, Research Informatics, Laboratory Informatics, Enterprise Quality Management, Environmental Health & Safety and Operations help optimize the scientific innovation lifecycles of our customers. Additionally, our software manages and connects scientific processes and information with other lifecycle systems, including Enterprise Resource Planning (ERP) and Product Lifecycle Management (PLM) systems.

The new products and domain expertise we have gained as a result of our acquisitions over the past three years, including QUMAS, ChemSW, Vialis, Aegis, VelQuest and Contur provide greater value to the development, QA/QC and manufacturing functions of our customer organizations. Our strategy is to continue to integrate and augment these offerings to further enhance the value of the products and expertise we acquired and our overall product portfolio. The combined Qumas and Accelrys product portfolios provide the industry’s only complete solution supporting quality and regulatory compliance across the product lifecycle, from product ideation through R&D to quality, manufacturing and out to the supply chain. The integration of ChemSW’s inventory management software into Accelrys' robust enterprise platform enables our combined customer base to comply with challenging global, national and local environmental health & safety regulations. The Aegis Acquisition further expands our downstream footprint with Accelrys Discoverant, the industry-leading Operations Intelligence software solution. TheVelQuest acquisition extends our software portfolio into pharmaceutical development, QA/QC and manufacturing improving productivity, speeding cycle times, lowering operational costs and reducing compliance risks for regulated life sciences organizations. Finally, the Contur acquisition allows us to offer an on-premises and cloud-based ELN for use by small- and medium-sized businesses and academic organizations focused on IP capture and information sharing, process documentation and overall lower total cost of ownership.

Our strategy also includes offering professional services to tailor the Accelrys Enterprise Platform to our customers’ individual business needs, thereby increasing the utility and value of the Accelrys Enterprise Platform. Because the Accelrys Enterprise Platform is the underlying operating infrastructure for many products in our broad portfolio, and integration with the applications obtained as part of our acquisition strategy continues to be a development priority, we expect the use of these products to expand as the use of the platform grows, thus further increasing our sales and value to customers. The Vialis Acquisition adds new services capabilities to our portfolio and further strengthens our position in the Laboratory Informatics software market.

The Accelrys Enterprise Platform is an open, scientifically aware platform. We partner with third-party organizations and academic institutions that develop scientific software and services, and we enable and encourage these companies to develop applications that operate on our platform, further extending its utility and value to customers.

We also focus on industries in markets where scientific innovation is a key differentiator and where our depth of experience from research to manufacturing and our proven enterprise solutions are highly valued. With over 225 Ph.D. scientists within our global workforce, we are deeply invested in science. As we increase our presence in science-driven markets within the pharmaceutical, biotechnology, energy, chemicals, food and beverage and consumer packaged goods sectors, we believe our ability to attract additional customers will increase.

Products and Services

The following is a brief description of the major product and services offerings within the Accelrys solution portfolio:

Scientific Platform Data Management

Scientific platform and data management capabilities are foundational to Accelrys’ capabilities to design, develop and deploy scientific informatics software solutions across the active workspace we serve, including modeling and simulation, research informatics, laboratory informatics, enterprise quality management, environmental health and safety, and operations intelligence. The ability to move data, information and knowledge seamlessly up and down the product development continuum from upstream product ideation through R&D to downstream QA/QC operations enhances organizational efficiency, improves collaboration and speeds innovation in lab-to-plant processes, enabling organizations to bring better products to market more quickly.

The Accelrys Enterprise Platform forms the basis of Accelrys’ software and services offerings and is central to our strategy to develop and deliver scientific innovation lifecycle management software. The Accelrys Enterprise Platform’s open, scientifically aware, service-oriented architecture provides a broad, flexible foundation optimized to integrate the diversity of science, experimental processes and information requirements across the research, development, QA/QC and manufacturing phases of product development. The Accelrys Enterprise Platform leverages Accelrys’ deep domain expertise in modeling and simulation, research informatics, laboratory informatics, enterprise quality management, environmental health and safety, and operations intelligence, improving collaboration, speeding innovation and enabling organizations to bring better products to market more quickly and efficiently. The Accelrys Enterprise Platform manages structured and unstructured information encountered early in the innovation cycle, as well as highly structured automated batch records required by lock-down production. We are integrating many of our acquired products into the Accelrys Enterprise Platform to enhance the value of both the products and the Accelrys Enterprise Platform. The Accelrys Enterprise Platform’s ability to integrate with existing infrastructure allows organizations to gain efficiencies from their legacy systems, reduce complexity and improve productivity from innovation through commercialization.

The Accelrys Component Collections operate with the Accelrys Enterprise Platform to offer customers advanced functions such as image, text and chemical analysis. The Accelrys Component Collections enable researchers, developers and IT professionals to build, deploy, analyze and report on complex scientific data types, improving processes, accelerating decisions and lowering costs. The Accelrys Component Collections are available to all Accelrys applications, as well as to Accelrys partner solutions and other third-party applications.

The Accelrys Pipeline Pilot scientific workflow authoring application allows scientists to rapidly create, test and publish services that automate the process of accessing, analyzing and reporting data, either for the scientist’s personal use or for sharing across the scientific community. Using Pipeline Pilot, scientists, researchers, engineers and analysts with little or no software development experience can create scientific protocols that can be executed through a variety of interfaces or solutions, including Accelrys Web Port, Accelrys Electronic Lab Notebook, Accelrys Insight, and Accelrys Chemical Registration, as well as third-party applications such as Microsoft SharePoint or customer-developed applications. These protocols aggregate and provide immediate access to volumes of disparate data locked in silos, automating data analysis and enabling researchers to rapidly explore, visualize and report results.

Modeling and Simulation

Accelrys offers a broad array of software products based on proprietary and licensed technologies that allow scientists to perform computations of chemical, biological and materials properties; to simulate, visualize and analyze chemical and biological systems; and to communicate the results to other scientists. Our modeling and simulation products are used by scientists in the life science industry, primarily by pharmaceutical and biotechnology companies, and by researchers in materials sciences industries such as specialty chemicals, formulated consumer packaged goods, food & beverage and oil & gas.

Accelrys Discovery Studio is Accelrys’ premier modeling and simulation product for chemistry small molecule and biology macromolecule-based research. Built on Accelrys Enterprise Platform technology, Accelrys Discovery Studio features an open architecture that allows scientists to “plug and play” best-of-breed computational solutions developed by Accelrys, academia, other independent software vendors or customers themselves. This open architecture helps expert modelers deploy modeling methods to research colleagues, connecting them more effectively with the wider research community. Accelrys Discovery Studio automates routine predictive science tasks and rapidly integrates with third-party applications, uniquely

positioning the software as the most comprehensive, collaborative life sciences research solution for experts and project teams alike.

Accelrys Materials Studio is a complete modeling and simulation environment designed to allow researchers in materials science and chemistry to engineer new, high-performance materials by predicting and understanding the relationships of a material’s atomic and molecular structure with its properties and behavior. Using Accelrys Materials Studio, researchers in many industries are engineering better performing materials of all types including pharmaceuticals, catalysts, polymers, composites, metals, alloys, batteries, fuel cells and more-as an integrated part of their scientific innovation management lifecycle strategy. Materials Studio is now integrated with the Accelrys Enterprise Platform, enabling organizations to extend predictive capabilities and deploy modeling and simulation to the enterprise.

Research Informatics

Accelrys is a leading provider of software-based solutions designed to capture, store, manage, analyze, mine and report discovery data and information across many industries including pharmaceutical, biotechnology, agrochemical, fine and specialty chemicals, consumer packaged goods, and oil and gas. As leaders in the space, we have developed a go-forward roadmap that leverages the best technology from each of the product portfolios gained through the acquisitions we have made over the past few years. This roadmap preserves our customers' investments, while offering a solution that addresses the needs of today's scientific organizations. Through this combined portfolio, our comprehensive data visualization and analysis software components based on a services-oriented architecture enabling scientists to search, retrieve and use chemical structures, biological and chemical data, experimental data and registration information. Many of these tools use industry standard software components and are compatible with applications such as Microsoft Excel spreadsheets and Microsoft SharePoint collaboration software, allowing scientists to interact with chemical data using familiar productivity tools. We also combine this component technology with the Accelrys Enterprise Platform and our database architectures to build enterprise-wide systems for clients.

The Accelrys Cheminformatics Suite is a set of applications, built upon or integrated with the Accelrys Enterprise Platform, that enables scientists to register, search, mine and analyze information on chemical structures and reactions, chemically modified sequences and associated data such as inventory, assay and analytical results. Key applications in the suite include Accelrys Pipeline Pilot and the following cheminformatics products:


•	Accelrys BioRails - Comprehensive support for tracking, planning and execution of biological experiments within pharmaceutical organizations;


•	Accelrys Cheshire - Custom cheminformatics business rules enabling R&D organizations to standardize chemical and biological sequence registration, structure queries, displays and calculations;


•	Accelrys Direct - The preeminent chemistry data cartridge for Oracle databases supporting the capture and management of structures, reactions and biological sequences;


•	Accelrys Draw - Industry-leading chemistry drawing software for the accurate representation, registration and searching of structures, reactions and biological sequences, and the production of publication-quality graphics;


•	Accelrys Chemical Registration - A flexible, fully featured, out-of-the-box solution for building, managing and searching a corporate substance and batch database; and


•	Accelrys Biological Registration - A multi-entity system for defining, registering, relationship-tracking, querying and reporting on biological entities.

Additional key applications and solutions within Research Informatics include:

The Accelrys Externalized Collaboration Suite addresses the needs of life sciences organizations engaged in externalized network research, supporting the full range of needs from technology transfer through networked collaboration to scientific informatics across all research data including experiments, chemical structures, assays and other test results. The result is a more holistic externalization strategy for partnering pharmaceutical, contract research, biotechnology and academic organizations as well as increased flexibility, reduced complexity and improved operational excellence in collaborative network research.

Accelrys Insight helps life scientists collaborate more effectively with internal teams and across networked external organizations to make fast, informed decisions about how to move research projects to the next level. Using Accelrys Insight, scientists can search and import data quickly and easily, browse and visualize data in detail, filter and combine data, visualize data using a variety of linked and interactive views and run extensive calculations and analytics in a collaborative environment.

Accelrys Insight for Excel provides scientific data analysis capabilities within the familiar Microsoft Excel spreadsheet environment, supporting rapid decision-making through the effective aggregation, analysis and presentation of data.

Accelrys Content Databases are a comprehensive, integrated and cross-referenced collection of factual databases and reference works covering chemical sourcing, molecular properties and bioactivity (metabolism and toxicology) information. These resources can be accessed through the Accelrys Electronic Lab Notebook, data management and informatics applications or via the Internet through the DiscoveryGate portal.

ScienceCloud by Accelrys is a new information management and collaboration workspace in the cloud that advances collaborative drug discovery with a new generation of integrated, SaaS-based applications built on a scalable, world-class scientific platform. A step in the Accelrys’ externalized collaboration initiative, ScienceCloud supports data and information storage in a secure, project-specific information warehouse in the cloud, while also helping project teams leverage social communication to build and share project information. The result is a more holistic collaboration strategy for partnering pharmaceutical and biotechnology companies, contract research organizations and academic research teams.

Laboratory Informatics

Accelrys process management and compliance software solutions support rapid process development, optimization, validation and scale-up, all the way to highly efficient, compliant process execution, connecting lab-to-plant workflows and information across the innovation to commercialization lifecycle. Scientists can rapidly explore and document early investigations while developing new methods, recipes and processes with domain-specific templates and capabilities for process, formulation and analytical scientists. Once new operating procedures have been developed, these can be passed into a lock-down automated environment for right-first-time compliant execution by analysts, operators and engineers in QA/QC and manufacturing operations.

Accelrys electronic lab notebooks (“ELNs”) replace the paper notebooks traditionally used by scientists, providing a digital environment in which scientists can plan, execute, record, store, back-up and share their daily research activities. In combination with the Accelrys Enterprise Platform, Accelrys ELNs offer scientists the opportunity to streamline the processes associated with experiment planning, design, execution and analysis by standardizing on a single, multi-disciplinary notebook that incorporates Accelrys Pipeline Pilot’s analysis and reporting capabilities. The following Accelrys ELNs are continually being enhanced with new domain-specific capabilities for scientists engaged in discovery, process, analytical, formulations and biology functions.

The Accelrys Electronic Laboratory Notebook (formerly Symyx Notebook by Accelrys) is an enterprise ELN designed to be used across multiple scientific disciplines and is particularly suited for regulated environments. The Accelrys Electronic Lab Notebook efficiently manages the flow of information, tasks and materials among scientists, software and instruments within and between labs, improving personal productivity, collaboration and collective intelligence. When combined with the Accelrys Lab Execution System, the Accelrys Electronic Lab Notebook provides a unique and ideal environment for rapidly optimizing and validating methods and recipes in compliant quality operations.

Accelrys Notebook (formerly Contur ELN) and Accelrys Notebook Cloud (formerly iLabber Cloud) are flexible, multi-disciplinary, low-cost-of-ownership ELNs that improve information sharing/reuse, data protection, process documentation and overall productivity. Both ELNs provide a high degree of flexibility and fast time to productivity while still meeting the requirements of both small to mid-size companies and large global enterprises. Accelrys Notebook is an easy-to-use, easy-to-deploy on-premises installation, while Accelrys Notebook Cloud is a secure, zero-install, SaaS-based system hosted in a secure, compliant-ready environment.

Customers deploying Accelrys Electronic Lab Notebook, Accelrys Notebook or Accelrys Notebook Cloud see significant productivity gains resulting from improved use and sharing of research data across the enterprise. The ELNs also improve data and documentation quality while enhancing compliance with standard operating procedures.

Accelrys Lab Execution System (“Accelrys LES,” formerly VelQuest SmartLab) provides an electronic environment that removes paper processes and automates the interaction with methods, instruments and supplies that scientists and analysts use every day in regulated QA/QC environments. By automating procedure execution in compliant quality operations, Accelrys LES eliminates paper-based inefficiencies, increases resources to improve capacity, removes transcription and calculation errors that are common in paper notebooks and accelerates reporting/review cycles.

Accelrys Electronic Batch Records (“Accelrys EBR,” formerly VelQuest SmartBatch EBR) is an out-of-the-box procedure execution and electronic batch record software system that provides a low-cost-of-ownership, electronic environment for efficiently and compliantly documenting the execution of procedures and recipes. Accelrys EBR is designed for organizations that want improved batch record keeping and compliance without the large overhead of a complex manufacturing execution system.

Accelrys LIMS is an entirely new process and execution-centric approach to laboratory information management systems (“LIMS”) implementations that is fundamentally different from the sample-driven approach of traditional LIMS. This entirely new approach eliminates the complexities, excessive customization and associated lengthy validation requirements inherent with legacy LIMS, offering fast, “out-of-the-box” deployment with no custom coding, easy integration into existing software platforms and enterprise-wide data management capabilities. The result is faster deployment, substantially lower total cost of ownership and rapid time to value. Accelrys LIMS applications include commercial, off-the-shelf applications supporting environmental monitoring, inventory management, metrology and calibration management, sample and specification management, stability study management and work request management.

Accelrys Experiment Knowledge Base (Accelrys EKB) is a first-in-class research and development-focused laboratory informatics system that enables R&D organizations to more efficiently analyze, manage and mine knowledge from their experiments and data. Accelrys EKB represents a new approach to lab informatics in R&D that enables multiple users to view experiment data in ways specific to their needs, providing the “right tool” for the “right task.” Previously offered as a services-based solution, Accelrys EKB is now a commercial product that has proven to reduce research costs and accelerate product development in chemicals, bioprocessing, energy, catalysis, food & beverages, formulations and other applications.

Enterprise Quality Management

Accelrys’ acquisition of Qumas in December 2013 has extended our software portfolio with mission-critical, end-to-end content and process compliance solutions for highly regulated industries. Available as SaaS, private Cloud or on-premises deployments, these solutions scale to thousands of users and millions of documents, while supporting externalized collaboration with third parties and partner communities. Qumas provides an electronic document management application with related R&D submission and quality assurance documentation packages based on customer and industry requirements and best practices. Qumas’ business process management applications include corrective action/preventive action, audit, change control, deviation, complaint and other critical process packages offering pre-defined and pre-tested software configurations addressing common compliance challenges. These proven compliance and quality management solutions advance scientific innovation lifecycle management by reducing regulatory risks, lowering quality costs, improving compliance effectiveness and increasing operational efficiency in bringing new products to market.

Environmental Health and Safety

Accelrys’ acquisition of ChemSW in September 2013 has extended our software portfolio with a unique Environmental Health and Safety (EH&S) solution that tracks and manages chemical inventory, making it easier for companies to adhere to global, national, state and local regulatory and safety requirements. This EH&S compliance software advances scientific innovation lifecycle management by providing solutions for managing and tracking the source, use and disposal of chemicals along the entire lab-to-plant value chain.

The Accelrys CISPro Chemical Inventory System offers customers an automated inventory system for tracking and tracing chemicals including: monitoring and tracking location and quantity specifics; monitoring usage; generating reports and quickly assessing hazard information during an emergency. Offered as both an on-premises and a cloud-based solution, Accelrys CISPro makes current, real-time chemical safety and inventory data available on-demand, helping to drive safe chemical handling, storage and management.

Operations Intelligence

Effective Operations Intelligence requires flexible, real-time data access technology combined with extensive analytical and statistical tools to help customers capture, manage and analyze development and process data used in new product development and commercial manufacturing and quality operations. This comprehensive software offering enables organizations to understand not only what is happening in manufacturing but also why it is happening across the entire process (i.e., cause-and-effect analysis). This contrasts with most manufacturing software systems that only allow organizations to see what is happening in a portion of the process (i.e., descriptive analysis) without necessarily understanding why.

Accelrys Discoverant is a validatable Operations Intelligence application (previously Aegis Discoverant) that aggregates, contextualizes and analyzes manufacturing, quality and product development data, helping quality and manufacturing organizations gain visibility into their process data to improve overall process understanding. By integrating powerful ad hoc investigational analytics with a unique data modeling technology, the software provides real-time, on-demand data access, analysis and reporting of manufacturing and process development data on-demand by the end users, reducing supply chain costs by making manufacturing process outcomes more predictable.

Services

The value of our software is enhanced by robust service offerings including Accelrys Consulting, Accelrys Management Consulting, Accelrys Support and Accelrys Education, all of which provide a variety of options to our clients and create greater returns on their investments.

Accelrys Consulting focuses on the implementation, deployment, migration and integration of scientific solutions while also enhancing the value of Accelrys software products by extending out-of-the-box functionality to address clients’ specific business needs. Leveraging the Accelrys Enterprise Platform, the group delivers a range of solutions, from software wrappers that allow customers to run their own algorithms on the platform to enterprise-wide informatics systems that integrate customers' internal systems with software from many vendors, including Accelrys. The group specializes in deploying systems for use by customers in all domains, from early research to early product manufacturing.

Accelrys Management Consulting (previously Vialis Paperless Lab Solutions) further offers professional consulting services in business analysis, laboratory process excellence, multi-moment analysis, business case justification, vendor solution selection, integration consulting and solution support across the entire value and knowledge creation chain from research to production. Accelrys Management Consulting combines unparalleled lab-to-plant business consulting services with unique, multidisciplinary domain expertise enabling on-time/on-budget delivery of consistent processes throughout the customer’s organization.

Accelrys Support is engaged in resolving, tracking and escalating customer issues through a global customer support center, providing access to new product releases, technical notes, documentation addenda and other support which collectively empower customers to utilize our products more effectively. The group also provides telephone, e-mail, fax and Internet-based support services, assists with user group meetings and offers targeted contract services involving application of our technology and scientific expertise to meet particular research needs of customers. Technical newsletters and bulletins are sent to customers to keep them informed and to help them with resource allocation and scheduling. We believe that customer service, support and training are essential to the successful adoption and utilization of our products.

Accelrys Education offers training conducted by staff that is knowledgeable in both the theory and application of Accelrys products. Our tailored e-learning, on-site and web-based training services ensure that clients can quickly install our products and become expert users of our solutions.

Customers

Our customer base consists of companies that differentiate themselves from the competition on the basis of scientific innovation. These customers include commercial, governmental and academic organizations including many of the world's largest pharmaceutical, biotechnology, energy, chemicals, food and beverage and consumer packaged goods companies. No single customer accounted for more than 10% of our revenue during any of the three most recently completed fiscal years.

Strategic and Academic Alliances

We have entered into a number of strategic alliances relating to product development, product distribution and joint marketing. We plan to continue to cultivate relationships with academic, governmental and commercial research organizations for purposes of identifying and licensing new technology to use in product development. In addition, we plan to maintain and expand our alliances focusing on the compatibility of our products with databases and database management systems, other computational chemistry and molecular simulation solutions and products in related markets such as imaging and clinical informatics. We also intend to continue to enter into integration and joint marketing arrangements with systems integrators and original equipment manufacturer partners.

Sales and Marketing

We market our products and services worldwide. During the year ended December 31, 2013, we generated 49%, 31% and 19% of our revenues from the U.S., Europe and the Asia/Pacific region, respectively. Please refer to Note 1 to our consolidated financial statements included elsewhere in this Report for a breakdown of revenues and long-lived assets by geographic region. Our continuing reliance on sales in international markets exposes us to risks attendant to foreign sales, as described more fully in Item 1A of this Report.

We sell our products and services through our direct sales force, telesales and, in some markets, arrangements with distributors. Our direct sales representatives focus on a defined list of customers or cover an assigned geographic territory. These direct sales representatives typically work closely with our pre-sales scientists to demonstrate our products and their

applicability to various research and development efforts. Our telesales effort is directed at smaller commercial accounts and academic institutions. Our distributor relationships primarily exist in the Asia/Pacific region, specifically in Japan, China and Korea, and complement our direct sales force in those markets.

In support of our sales activities, we participate in industry trade shows, publish our own newsletter, advertise in industry publications and via Internet search engines, publish articles in industrial and scientific publications, conduct direct e-mail campaigns, sponsor industry conferences and seminars and maintain a website that contains information about us and our product and service offerings.

Our products, together with the associated product literature, are generally delivered to our customers at the time of placing and processing their order. Our electronic software distribution program allows our customers to download our products over the Internet.

Our customers' buying habits have historically resulted in a higher concentration of sales in the fourth quarter of the calendar year, due to traditionally higher purchasing activity in the month of December in many commercial organizations.

Product Development

Development of our software is focused on expanding product lines, designing enhancements to our core technology and integrating existing and new products into our principal software architecture and platform technology. We intend to offer regular updates to our products and to continue to look for opportunities to expand our existing product offerings.

We develop most of our products internally and, during the years ended December 31, 2013, 2012 and 2011, we incurred product development expenses of $37.5 million, $38.8 million and $34.0 million, respectively. We have also licensed products or have otherwise acquired products, or portions of our products, from the open source community, as well as corporate, governmental and academic institutions. These arrangements sometimes involve joint development efforts and frequently require the payment of royalties by us. The development and royalty obligations, scope of distribution rights, duration and other terms of these arrangements vary depending on the product, the market, resource requirements, the other parties with which we contract and other factors. We intend to continue to license or otherwise acquire technology or products from third parties.

Competitors

We believe our Accelrys Enterprise Platform and our approach to managing the innovation lifecycle is unique, and that the market for the platform is at an early stage, with limited established competition from commercial software vendors. We also believe that industry trends such as externalization and increased cost and regulatory pressures will continue to drive organizations to optimize their lab-to-commercialization value chains and to seek ways to better innovate. The competition for our enterprise platform includes our customers’ own proprietary software, open source software such as Knime and workflow and data-pipeline applications of smaller commercial software vendors such as IDBS.

The markets for our informatics software products and our modeling and simulation products for the pharmaceutical and biotechnology industries are mature and intensely competitive, subject to rapid change and significantly affected by new product introductions and other market activities of industry participants. Our competitors offer a variety of products and services to address this market. We believe that the principal competitive factors in this market are product quality, flexibility, ease-of-use, scientific validation and performance, functionality and features, open architecture, quality of support and service, reputation and price. Competition currently comes from open-source software, our customers' internal tools and the following commercial software vendors (listed by product type and competitors that supply such products): other software packages for analysis of chemical and biological data (IDBS); desktop and web-based software applications (Perkin Elmer/CambridgeSoft and Tripos) including chemical drawing applications (Perkin Elmer/CambridgeSoft); molecular modeling and analytical data simulation applications (Chemical Computing Group, OpenEye, Schrödinger and Tripos); and database management systems and information technology (IDBS).

Our ELN and Accelrys LES solutions face competition from commercial software vendors in two primary areas: enterprise-wide deployments of ELN or LIMS (Perkin Elmer/CambridgeSoft, IDBS, LabWare, LabVantage, Waters); and smaller, department-focused initiatives (Perkin Elmer/CambridgeSoft, IDBS and Recentris).

The market for our modeling and simulation offerings aimed at the energy, chemicals, aerospace and consumer packaged goods industries is in its early stages with limited and fragmented competition from established software vendors. The industries that these offerings target generally rely on data from experiments rather than utilizing computer-aided design modeling and simulation software to obtain such data. Our limited competition from commercial software vendors in these

industries currently comes from smaller competitors such as Gaussian Inc., Materials Design Inc., Schrödinger Atomistix and Scienomics.

Backlog of Committed Revenue

As of December 31, 2013, our backlog was approximately $171.5 million, compared with $153.7 million as of December 31, 2012. We expect to recognize approximately $135.6 million of our December 31, 2013 backlog during fiscal 2014. Our backlog consists of contractual commitments from our customers for products to be shipped, research, consulting and maintenance services to be provided, and license and content revenue to be recognized. Because of the occasional customer-driven changes in delivery schedules or cancellation of orders without significant penalty, we do not believe our backlog, as of any particular date, is necessarily indicative of actual revenue for any future period.

Intellectual Property and Other Proprietary Rights

We rely primarily on a combination of copyright, trademark and trade secret laws, confidentiality procedures and contractual provisions to protect our proprietary rights. We also have been issued numerous patents in the U.S. and abroad, covering a wide range of our technology. We believe that factors such as the technological and creative skills of our personnel, new product development, frequent product enhancements, name recognition and reliable product maintenance are essential to establishing and maintaining a technological leadership position. There can be no assurance that our means of protecting our proprietary rights in the U.S. or abroad will be adequate. We seek to protect our software, documentation and other written materials under trade secret and copyright laws, which afford only limited protection. Further, there can be no assurance that our patents will offer any protection or that they will not be challenged, invalidated or circumvented.

Employees

As of December 31, 2013, we had 735 full-time employees. None of our employees are covered by collective bargaining agreements. Substantially all of our employees, other than certain of our executive officers and employees with customary employment arrangements within Europe and Asia, are at will employees, which means that each employee can terminate his or her relationship with us and we can terminate our relationship with him or her at any time. We offer industry competitive wages and benefits and are committed to maintaining a workplace environment that promotes employee productivity and satisfaction. We believe our relations with our employees are good.

Website Access to SEC Filings

We are subject to the reporting requirements under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Consequently, we are required to file reports and information with the SEC, including reports on the following forms: annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act. These reports and other information concerning us may be accessed through the SEC’s website at http://www.sec.gov and on our website at www.accelrys.com. Such filings are placed on our website as soon as reasonably practical after they are filed with the SEC. Any information contained in, or that can be accessed through our website, is not incorporated by reference into, nor is it in any way part of this Report.



Item 1A.	Risk Factors

You should carefully consider the risks described below before investing in our publicly traded securities. The risks described below are not the only ones facing us. Our business is also subject to the risks that affect many other companies, such as competition, technological obsolescence, labor relations, general economic conditions, geopolitical changes and international operations. Additional risks not currently known to us or that we currently believe are immaterial also may impair our business operations and our liquidity. The risks described below could cause our actual results to differ materially from those contained in the forward-looking statements we have made in this Report, the information incorporated herein by reference and those forward-looking statements we may make from time to time.

Risks Relating to the Pending Transactions

The announcement and pendency of the Merger Agreement and the transactions contemplated thereby, including the Offer and the Merger (collectively, the “Transactions”), could adversely affect our business, financial results and operations.

As a result of the execution of the Merger Agreement with DSAC and Purchaser, and irrespective of whether or not the Transactions are completed, the uncertainty of the Transactions could cause disruptions in our business, including, but not limited to, the following:

•

New or existing customers may prefer to enter into agreements with our competitors who have not expressed an intention to sell their business because customers may perceive that such new relationships are likely to be more stable. As a result of our execution of the Merger Agreement and the announcement of the Transactions, other third parties may be unwilling to enter into material agreements with us;


•	Current and prospective employees of the Company may experience uncertainty about their future roles with the Company, which might adversely affect our ability to retain or attract key management and other employees; and


•	The attention of our management may be diverted from the operation of the businesses toward the completion of the Transactions.

The occurrence of any of these events individually or in combination could adversely affect our business, financial results and operations.

There is no assurance that the Transactions will be completed.

We cannot assure you that the Transactions will be consummated in the expected time frame or at all. The consummation of the Transactions is subject to the satisfaction or waiver of a number of conditions which have not yet been satisfied as of this date, including, with respect to the Offer, the tendering by the Company’s stockholders of over 50% of the outstanding shares of the Company’s common stock, calculated on a fully diluted basis. No assurance can be given that the remaining conditions to Transactions will be satisfied. In addition, DSAC may terminate the Merger Agreement in circumstances including if events, changes or developments occur that have a material adverse effect on our business as defined in the Merger Agreement.

If the Transactions, or similar transactions, are not completed, the share price of our common stock may change, insofar as and to the extent that the current market price of our common stock reflects an assumption that the Transactions, or a similar transaction, will be completed. We also will have incurred significant costs, including the diversion of management resources, for which we will have received little or no benefit. In addition, if the Transactions are not consummated, we may not be able to develop and implement a strategy for the future growth and development of the Company’s business that would generate a return similar to or better than the return which would be generated by the Transactions.

The Merger Agreement imposes restrictions on our ability to operate the Company, which may delay or prevent us from undertaking business opportunities that may be beneficial to the Company, pending completion of the Transactions.

The Merger Agreement contains restrictions on our ability to operate the Company prior to the consummation of the Transactions. These restrictions could harm us by, among other things, prohibiting, limiting or restricting our ability to take advantage of mergers, acquisitions and other corporate opportunities or to take certain actions that management may deem to be necessary or desirable to operate or grow the Company or to increase its profitability.

We are not permitted to terminate the Merger Agreement except in limited circumstances, and we may be required to pay a substantial termination fee to DSAC if the Merger Agreement is terminated.

We may only terminate the Merger Agreement in limited circumstances. If the Merger Agreement is terminated in certain circumstances for specified reasons, we will be obligated to pay a termination fee of $25.0 million.

Lawsuits have been filed against Accelrys, the members of our board of directors, DSAC, Purchaser and, in one case, Dassault Systèmes SA challenging the proposed Transactions, and an adverse judgment in such lawsuits, or any similar lawsuit, may prevent the Transactions from being consummated or from being consummated within the expected timeframe, and may result in costs to Accelrys.

As described in greater detail elsewhere in this Report, Accelrys, the members of our board of directors, DSAC, Purchaser and, in one case, Dassault Systèmes SA are named as defendants in two putative class action lawsuits filed in the Court of Chancery of the State of Delaware by purported stockholders of Accelrys, on behalf of the stockholders of Accelrys, challenging the proposed Transactions, and seeking, among other things, (i) preliminary and permanent injunctive relief enjoining the defendants from consummating the Transactions pursuant to the terms of the Merger Agreement, (ii) injunctive relief enjoining the Merger Agreement as invalid and unenforceable, or in the alternative, amending or enjoining the deal protection provisions of the Merger Agreement as necessary to ensure a full and fair sales process for the benefit of the plaintiffs, and unless or until the defendants disclose all material information to the Accelrys stockholders, (iii) damages, (iv) imposition of a constructive trust in favor of the plaintiffs with respect to any benefits improperly received by the defendants as a result of their alleged wrongdoing and (v) recovery of attorneys' fees and other fees and costs. One of the conditions to the completion of the Transactions is that no preliminary or permanent injunction or other order prohibiting or otherwise preventing the consummation of the Transactions shall have been issued by any governmental entity of competent jurisdiction in the U.S., Germany or Austria. Consequently, if any of the plaintiffs in the above referenced lawsuits, or in any other subsequently filed similar lawsuit, is successful in obtaining an injunction prohibiting the parties from completing the Transactions on the agreed-upon terms, the injunction may prevent the completion of the Transactions in the expected timeframe, or at all.

Accelrys has obligations under certain circumstances to hold harmless and indemnify each of the defendant directors against judgments, fines, settlements and expenses related to claims against such directors and otherwise to the fullest extent permitted under Delaware law and Accelrys’ bylaws and certificate of incorporation. Such obligations may apply to the lawsuit. Accelrys and the Accelrys Board believe the respective allegations against them in the complaints are wholly without merit, and intend to vigorously defend against those allegations. However, there can be no assurance that the defendants will be successful in their defense. An unfavorable outcome in any lawsuit related to the Transactions could prevent or delay the consummation of the Transactions, result in substantial costs to Accelrys or both.

Certain Risks Related to Our Marketplace and Environment

Our revenue from the sale of computer aided design modeling and simulation software to the life science discovery research marketplace, which has historically constituted a significant portion of our overall revenue, has been declining over the past several years and may continue to decline in future years. Historically we have derived a significant portion of our revenue from the sale of computer aided design modeling and simulation software to the discovery research departments in pharmaceutical and biotechnology companies. Based on recurring analyses of incoming orders typically conducted by our sales and marketing departments, we estimate that orders for our computer aided design modeling and simulation software for the life science industry declined approximately 18% between fiscal 2008 and 2009, approximately 16% between fiscal 2009 and 2010, and approximately 21% during the nine months ended December 31, 2010. Although revenues remained relatively constant for fiscal, 2011, 2012, and 2013, in the future we may experience a decline in revenues. While there is not a linear correlation between product orders and resulting revenue, we believe that our estimates of decreased product orders ultimately reflect a decline in revenue attributable to sales of our computer aided design modeling and simulation software products. We believe this decline is due to several factors, including industry consolidation, a general reduction in the level of discovery research activity by our customers, increased competition, including competition from open source software, and reductions in profit and related information technology spending by our customers. If such declines continue and we do not increase the revenue we derive from our other product and service offerings, our business could be adversely impacted.

Our ability to sustain or increase revenues will depend upon our success in entering new markets and in deriving additional revenues from our existing customers. Our products are currently used primarily by molecular modeling and simulation specialists in discovery research organizations. One component of our overall business strategy is to derive more revenues from our existing customers by expanding their usage of our products and services. Such strategy would have our customers utilize our scientific informatics platform and our tools and components to leverage vast amounts of information stored in both corporate databases and public data sources in order to make informed scientific and business decisions during the research and development process. In addition, we seek to expand into new markets and new areas within our existing markets by acquiring businesses in these markets, attracting and retaining personnel knowledgeable in these markets, identifying the needs of these markets and developing marketing programs to address these needs. If successfully implemented, these strategies would increase the usage of our software and services by biologists, chemists, engineers and informaticians

operating within our existing pharmaceutical and biotechnology customers, as well as by new customers in other industries. However, if our strategies are not successfully implemented, our products and services may not achieve market acceptance or penetration in targeted new departments within our existing customers or in new industries. As a result, we may incur additional costs and expend additional resources without being able to sustain or increase revenue.

Our focus on offering scientific business intelligence solutions to both existing and new customers and markets may make it more difficult for us to sustain our revenue from the sale of computer aided design modeling and simulation products to the life science discovery research marketplace. Our strategy involves transforming our product and service offerings by utilizing our scientific informatics platform and our tools and components in order to enable our customers to more effectively utilize the vast amounts of information stored in both their databases and public data sources in order to make informed scientific and business decisions during the research and development process. This strategy is intended to lead us to new and different markets and customers, as well as increase the usage of our offerings by existing customers. Executing this strategy will require significant management focus and utilization of resources. Though we intend to continue to dedicate sufficient resources and management focus to our life science computer aided design modeling and simulation products, it is possible that the strategy will result in loss of management focus and resources relating to these existing products and markets, thereby resulting in decreasing revenues from these markets. If these revenues are not offset by increasing revenues from new markets and/or customers, our overall revenues will suffer.

We may be unable to develop strategic relationships with our customers. Our overall business strategy is to expand usage of our products and services by expanding our current customers' usage of our products and by marketing and distributing our solutions to a broader, more diversified group of biologists, chemists, engineers and informaticians operating throughout our customers' research and development organizations. A key component of this strategy is to become a preferred provider of scientific software and solutions. Becoming a preferred provider will require substantial re-training and new skills development within our sales and service personnel and deployment of a successful account-management sales model. We believe that developing strategic relationships with our customers may lead to additional revenue opportunities. However, executing this strategy may require significant expense, and there can be no assurance that any such relationships will develop or that such relationships will produce additional revenue or profit opportunities.

Consolidation within the pharmaceutical and biotechnology industries may continue to lead to fewer potential customers for our products and services. A significant portion of our customer base consists of pharmaceutical and biotechnology companies. Continued consolidation within the pharmaceutical and biotechnology industries may result in fewer customers for our products and services. If one of the parties to a consolidation uses the products or services of our competitors, we may lose existing customers as a result of such consolidation.

Increasing competition and increasing costs within the pharmaceutical and biotechnology industries may affect the demand for our products and services, which may affect our results of operations and financial condition. Our pharmaceutical and biotechnology customers' demand for our products is impacted by continued demand for their products and by our customers' research and development costs. Demand for our customers' products could decline, and prices charged by our customers for their products may decline, as a result of increasing competition, including competition from companies manufacturing generic drugs. In addition, our customers' expenses could continue to increase as a result of increasing costs of complying with government regulations and other factors. A decrease in demand for our customers' products, pricing pressures associated with the sales of these products and additional costs associated with product development could cause our customers to reduce research and development expenditures. Because our products and services depend on such research and development expenditures, our revenues may be significantly reduced.

Health care reform and restrictions on reimbursement may affect the pharmaceutical, biotechnology and industrial chemical companies that purchase or license our products or services, which may affect our results of operations and financial condition. The continuing efforts of government and third party payers in the markets we serve to contain or reduce the cost of health care may reduce the profitability of pharmaceutical, biotechnology and industrial chemical companies causing them to reduce research and development expenditures. Because some of our products and services depend on such research and development expenditures, our revenues may be significantly reduced. We cannot predict what actions federal, state or private payers for health care goods and services may take in response to any health care reform proposals or legislation.

We face strong competition in the life science market for computer aided design modeling and simulation software and for cheminformatics products. The market for our computer aided design modeling and simulation software products for the life science market is intensely competitive. We currently face competition from other scientific software providers, larger technology and solutions companies, in-house development by our customers and academic and government institutions and the open source community.

Some of our competitors and potential competitors in this sector have longer operating histories than we do and could have greater financial, technical, marketing, research and development and other resources. Many of our competitors offer products and services directed at more specific markets than those we target, enabling these competitors to focus a greater proportion of their efforts and resources on these markets. Some offerings that compete with our products are developed and made available at lower cost by government organizations and academic institutions, and these entities may be able to devote substantial resources to product development and also offer their products to users for little or no charge. We also face competition from open source software initiatives, in which developers provide software and intellectual property free over the Internet. In addition, many of our customers spend significant internal resources in order to develop their own software. Moreover, we intend to leverage our scientific informatics platform in order to enable our customers to more effectively utilize the vast amounts of information stored in both their databases and public data sources in order to make informed scientific and business decisions during the research and development process. This strategy could lead to competition from much larger companies which provide general data storage and management software.

There can be no assurance that our current or potential competitors will not develop products, services or technologies that are comparable to, superior to or render obsolete, the products, services and technologies we offer. There can be no assurance that our competitors will not adapt more quickly than us to technological advances and customer demands, thereby increasing such competitors' market share relative to ours. Any material decrease in demand for our technologies or services may have a material adverse effect on our business, financial condition and results of operations.

We are subject to pricing pressures in some of the markets we serve. The market for computer aided design modeling and simulation products for the life science industry is intensely competitive, which has led to significant pricing pressure and declines in average selling price over the past several years. Based on recurring analyses of incoming orders typically conducted by our sales and marketing departments, we estimate that the average sales price of our computer aided design modeling and simulation products for the life science industry declined approximately 10% between fiscal 2008 and 2009 and approximately 14% between fiscal 2009 and 2010. Although the average price remained relatively constant for fiscal 2011, 2012 and 2013, we may experience a decline in the future. While there is not a linear correlation between our product pricing and competition in the marketplace, we believe that our estimates of decreased prices ultimately reflect increased competition that has led and may continue to lead to pricing pressure with respect to sales of these products. In response to such increased competition and general adverse economic conditions in this market, we may be required to further modify our pricing practices. Changes in our pricing model could adversely affect our revenue and earnings.

Revenue from our database content business has been declining and may continue to decline. As a result of the Symyx Merger, we have acquired a database content business. This business faces intense competition from both third parties and the increasing availability of freely-available content databases. As a result, revenue from this database content business has been declining. If we are unable to reverse the decline in this business or to increase revenues from our other businesses in order to offset the decline, our revenues and results of operations may suffer.

Our operations may be interrupted by the occurrence of a natural disaster or other catastrophic event at our primary facilities. Our research and development operations and administrative functions are primarily conducted at our facilities in San Diego, California, San Ramon, California, Bend, Oregon, Milford, Massachusetts, Lafayette, Colorado, Durham, North Carolina, Cambridge, United Kingdom and Cork, Ireland. We also conduct sales and customer support activities at our facilities in Santa Clara, California, Bedminster, New Jersey, Burlington, Massachusetts, Paris, France, Basel, Switzerland, Cologne, Germany, Stockholm, Sweden Bangalore, India and Tokyo, Japan. Although we have contingency plans in effect for natural disasters or other catastrophic events, the occurrence of such events could still disrupt our operations. For example, our San Diego, San Ramon, and Tokyo facilities are located in areas that are particularly susceptible to earthquakes. Any natural disaster or catastrophic event in our facilities or the areas in which they are located could have a significant negative impact on our operations.

Our insurance coverage may not be sufficient to avoid material impact on our financial position or results of operations resulting from claims or liabilities against us, and we may not be able to obtain insurance coverage in the future. We maintain insurance coverage for protection against many risks of liability. The extent of our insurance coverage is under continuous review and is modified as we deem it necessary. Despite this insurance, it is possible that claims or liabilities against us may have a material adverse impact on our financial position or results of operations. In addition, we may not be able to obtain any insurance coverage, or adequate insurance coverage, when our existing insurance coverage expires. For example, we do not carry earthquake insurance for our facilities in Tokyo, Japan, San Ramon, California, or San Diego, California, because we do not believe the costs of such insurance are reasonable in relation to the potential risk.

Certain Risks Related to Our Operations

Defects or malfunctions in our products could hurt our reputation among our customers, result in delayed or lost revenue and expose us to liability. Our business and the level of customer acceptance of our products depend upon the continuous, effective and reliable operation of our software and related tools and functions. To the extent that defects cause our software to malfunction and our customers' use of our products is interrupted, our reputation could suffer and our revenue could decline or be delayed while such defects are remedied. We may also be subject to liability for the defects and malfunctions of third party technology partners and others with whom our products and services are integrated.

Delays in the release of new or enhanced products or services or undetected errors in our products or services may result in increased cost to us, delayed market acceptance of our products and delayed or lost revenue. To achieve market acceptance, new or enhanced products or services can require long development and testing periods, which may result in delays in scheduled introduction. Any delays in the release schedule for new or enhanced products or services may delay market acceptance of these products or services and may result in delays in new customer orders for these new or enhanced products or services or the loss of customer orders. In addition, new or enhanced products or services may contain a number of undetected errors or “bugs” when they are first released. Although we test each new or enhanced software product or service before it is released to the market, there can be no assurance that significant errors will not be found in existing or future releases. As a result, in the months following the introduction of certain releases, we may need to devote significant resources to correct these errors. There can be no assurance, however, that all of these errors can be corrected.

We are subject to risks associated with the operation of a global business. We derive a significant portion of our total revenue from our operations in international markets. During the years ended December 31, 2013, 2012 and 2011, 51%, 51% and 53% respectively, of our total revenue was derived from our international operations. Our global business may be affected by local economic conditions, including inflation, recession and currency exchange rate fluctuations. In addition, political and economic changes throughout the world may interfere with our or our customers' activities in particular locations and result in a material adverse effect on our business, financial condition and operating results. We anticipate that revenue from operations in international markets will continue to account for a significant percentage of future revenue. The following table depicts our region-specific revenue as a percentage of total revenue for the periods referenced:



	For the Years Ended
Region	December 31, 2013		December 31, 2012		December 31, 2011
U.S.	49	%	49	%	47	%
Europe	31	%	28	%	29	%
Asia-Pacific	19	%	23	%	24	%

Other potential risks inherent in our international business include:


•	unexpected changes in regulatory requirements;


•	longer payment cycles;


•	currency exchange rate fluctuations;


•	import and export license requirements;


•	tariffs and other barriers;


•	political unrest, terrorism and economic instability;


•	disruption of our operations due to local labor conditions;


•	limited intellectual property protection;


•	difficulties in collecting trade receivables;


•	difficulties in managing distributors or representatives;


•	difficulties in managing an organization spread over various countries;


•	difficulties in staffing foreign subsidiary or joint venture operations; and


•	potentially adverse tax consequences.

Our success depends, in part, on our ability to anticipate and address these risks. There can be no assurance that we will do so effectively, or that these or other factors relating to our international operations will not adversely affect our business or operating results.

In order to improve our financial position, we have implemented reduction-in-force plans, which could negatively impact our business. As a result of the Symyx Merger, we implemented a reduction-in-force of approximately 15% of the combined employee workforce after the Symyx Merger. In addition, in July 2013, we implemented a reduction-in-force of approximately 12% of our employee workforce. We do not believe that these reductions have had a material adverse effect on our operations or our ability to generate revenue to date. However, while we believe we have sufficient staff to operate our business, we do not have duplicative or redundant resources in many of our functions or operations. As a result, there can be no assurance that further attrition will not impact our ability to operate our business, or adversely impact our revenues.

Failure to attract and retain skilled personnel could have a material adverse effect on us. Our success depends in part on the continued service of key scientific, sales, business development, marketing, engineering, management and accounting personnel and our ability to identify, hire and retain additional personnel. There is intense competition for qualified personnel. Immigration laws may further restrict our ability to attract or hire qualified personnel. We may not be able to continue to attract and retain the personnel necessary for the development of our business. Failure to attract and retain key personnel could have a material adverse effect on our business, financial condition and results of operations. Further, we are highly dependent on the principal members of our technical, scientific and management staff and certain groups of consultants. One or more of these key employees or consultants could retire or otherwise leave our employ within the foreseeable future, and the loss of any of these people could have a material adverse effect on our business, financial condition or results of operations. We do not intend to maintain key person life insurance on the life of any employee.

Continued turmoil in the worldwide financial markets may negatively impact our business, results of operations, and financial condition. As widely reported, financial markets in the U.S., Europe and Asia have been experiencing disruption in recent years, including, among other things, volatility in security prices, declining valuations of certain investments, severely diminished liquidity and credit availability, the failure or sale of various financial institutions and an unprecedented level of government intervention. Many economists believe that the U.S. economy, and possibly the global economy, is in the midst of a prolonged recession. This protracted downturn may hurt our business in a number of ways, including through general decreases in spending and the adverse impact on our customers' ability to obtain financing, which may lead to delays or failures in our signing customer agreements or signing customer agreements at reduced purchase levels. While we are unable to predict the likely duration and severity of the current disruption in the financial markets and the adverse economic conditions in the U.S. and other countries, any of the circumstances mentioned above could have a material adverse effect on our revenues, financial condition and results of operations.

Recent acquisitions and potential future acquisitions could prove difficult to integrate, disrupt our business, dilute stockholder value and strain our resources. Since July 2010, we have acquired seven companies: Symyx, Contur, VelQuest, Aegis, Vialis, ChemSW and Qumas. We continually evaluate opportunities to acquire new businesses as part of our ongoing strategy and we may in the future acquire additional businesses that we believe could complement or expand our business or increase our customer base. We do not know if we will be able to complete any future acquisitions, or whether we will be able to successfully integrate any acquired businesses, operate them profitably or retain their key employees. Integrating the operations of acquired businesses successfully or otherwise realizing any of the anticipated benefits of any acquisitions, including anticipated cost savings and additional revenue opportunities, involves a number of potential challenges. The failure to meet these integration challenges could seriously harm our financial condition and results of operations. Realizing the benefits of our acquisitions or any future acquisitions depends in part on the integration of operations and personnel. These integration activities are complex, expensive and time-consuming and we may encounter unexpected difficulties or incur unexpected costs, including:


•	our inability to achieve the operating synergies anticipated in the acquisitions;


•	lost sales and customers as a result of our customers or customers of any acquired company deciding not to do business with us;


•	complexities associated with managing the larger, more complex, combined business;


•	integrating personnel from acquired companies while maintaining focus on providing consistent, high quality products;


•	potential unknown liabilities and unforeseen expenses, delays or regulatory conditions associated with acquisitions; and


•	diversion of management attention from ongoing business concerns to integration matters.

Acquired businesses may have liabilities or adverse operating issues that we fail to discover through due diligence prior to the acquisition. In particular, to the extent that prior owners of any acquired businesses or properties failed to comply with or otherwise violated applicable laws or regulations, or failed to fulfill their contractual obligations, we, as the successor owner, may be financially responsible for these violations and failures and may suffer reputational harm or otherwise be adversely affected. Acquisitions also frequently result in the recording of goodwill and other intangible assets which are subject to potential impairment in the future that could harm our financial results. As a result, if we fail to properly evaluate acquisitions or investments, we may not achieve the anticipated benefits of any such acquisitions, and we may incur costs in excess of what we anticipate.

In addition, in order to finance any acquisition, we may utilize our existing funds, thereby lowering the amount of funds we currently have, or might need to raise additional funds through public or private equity or debt financings. Prolonged tightening of the financial markets may impact our ability to obtain financing to fund future acquisitions and we could be forced to obtain financing on less than favorable terms. Additionally, equity financings may result in dilution to our stockholders, which could affect the market price of our stock.

Our ability to utilize our net operating loss (“NOL”) and tax credit carryforwards in the future is limited by Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (the “Code”). In general, under Sections 382 and 383 of the Code, a corporation that undergoes an “ownership change” is subject to limitations on its ability to utilize its pre-change NOL and tax credit carryforwards to offset future taxable income. In general, an ownership change occurs if the aggregate stock ownership of certain stockholders increases by more than 50 percentage points over such stockholders' lowest percentage ownership during the testing period (which is generally three years). The amount of the annual limitation is generally equal to the value of the stock of the corporation immediately prior to the ownership change, multiplied by the adjusted federal tax-exempt rate set by the Internal Revenue Service.

As a result of the Symyx Merger, Accelrys and Symyx have undergone an “ownership change” for purposes of Section 382 of the Code. Accordingly, the combined company's ability to utilize Accelrys' and Symyx's NOLs and tax credit carryforwards will be limited as described in the preceding paragraph. These limitations could in turn result in increased future tax payments for the combined company, which could have a material adverse effect on the business, financial condition or results of operations of the combined company.

Adverse resolution of litigation and other legal proceedings may harm our operating results or financial position. We are a party to lawsuits and other legal proceedings, most of which occur in the normal course of our business. Litigation and other legal proceedings can be expensive, lengthy and disruptive to normal business operations. Moreover, the results of complex legal proceedings are difficult to predict. An unfavorable resolution of a particular legal proceeding could have a material adverse effect on our business, operating results, financial position, and in some cases, on our reputation or our ability to obtain projects from customers, including governmental entities. See Item 1. Legal Proceedings and Note 15 of the notes to consolidated financial statements for more information regarding legal proceedings in which we are involved.

Certain Risks Related To Our Financial Performance

We have a history of losses and our future profitability is uncertain. We generated net losses for the year ended December 31, 2012, the nine months ended December 31, 2010, and the years ended March 31, 2007 and 2006. Although we generated net income for the years ended December 31, 2013, December 31, 2011, March 31, 2010, 2009 and 2008, we may experience future net losses which may limit our ability to fund our operations and we may not generate income from operations in the future. Our future profitability depends upon many factors, including several that are beyond our control. These factors include without limitation:


•	changes in the demand for our products and services;


•	the introduction of competitive software;


•	our ability to license desirable technologies;


•	changes in the research and development budgets of our customers and potential customers;


•	our ability to successfully, cost effectively and timely develop, introduce and market new products, services and product enhancements; and


•	the acquisition of any new entities or businesses which may have a dilutive effect upon our earnings.

Our sales forecast and/or revenue projections may not be accurate. We use a “pipeline” system, a common industry practice, to forecast sales and trends in our business. Our sales personnel monitor the status of proposals, including the date when they estimate a customer will make a purchase decision and the potential size of the order. We aggregate these estimates on a quarterly basis in order to generate a sales pipeline. While the pipeline process provides us with some guidance in business planning and forecasting, it is based on estimates only and is therefore subject to risks and uncertainties. Any variation in the conversion of the pipeline into revenue or the pipeline itself could cause us to improperly plan or budget and thereby adversely affect our business, results of operations and financial condition.

If we are unable to license software to, or collect receivables from, our customers, our operating results may be adversely affected. While the majority of our current customers are well-established, large companies and universities, we also provide products and services to smaller companies. Our financial success depends upon the creditworthiness and ultimate collection of amounts due from our customers, including our smaller customers with fewer financial resources. While we have not experienced significant customer defaults during 2011, 2012 and 2013 fiscal years, if we are not able to collect from our customers, we may be required to write-off significant accounts receivable and recognize bad debt expenses which could materially and adversely affect our operating results.

Our quarterly operating results, particularly our quarterly cash flows, may fluctuate. Quarterly operating results may fluctuate as a result of a number of factors, including lengthy sales cycles, market acceptance of new products and upgrades, timing of new product introductions, changes in pricing policies, changes in general economic and competitive conditions, and the timing and integration of acquisitions. We may also experience fluctuations in quarterly operating results due to general and industry specific economic conditions that may affect the research and development expenditures of pharmaceutical and biotechnology companies. In particular, historically we have received approximately two-thirds of our annual customer orders in the quarters ended December 31 and March 31. In accordance with our revenue recognition policies, the revenue associated with these orders is generally recognized over the contractual license term. Therefore, because we accrue sales commissions and royalties upon the receipt of customer orders, we have generally experienced an increase in operating costs and expenses during the quarters ended December 31 and March 31 with only a minimal corresponding incremental increase in revenue. Additionally, our cash flows from operations have historically been positive in the fiscal quarter ended March 31 as we collect the accounts receivable generated from these customer orders, while we have historically experienced negative cash flows from operations in the other three fiscal quarters. As a result of these seasonal variations, we believe that quarter-to-quarter comparisons of our operating results are not a good indication of our future performance and that our interim financial results are not necessarily indicative of results for a full year or for any subsequent interim period.

We may be required to indemnify Pharmacopeia Drug Discovery, Inc. (“PDD”), or may not be able to collect on indemnification rights from PDD. On April 30, 2004, we spun-off our drug discovery subsidiary, PDD, into an independent,

separately traded, publicly held company through the distribution to our stockholders of a dividend of one share of PDD common stock for every two shares of our common stock. As part of the spin-off, we agreed to indemnify the indebtedness, liabilities and obligations of PDD. One such obligation includes a guarantee by us to the landlord of PDD’s obligations under certain facility leases, with respect to which PDD will indemnify us should we be required to make any payment under the guarantee. These indemnification obligations could be as significant as the remaining future minimum lease payments, which totaled approximately $6.2 million as of December 31, 2013. PDD’s ability to satisfy any such indemnification obligations (including, without limitation, PDD’s commitment to indemnify us in the event of our payment under our guarantee of its leases) will depend upon PDD’s future financial strength. We cannot assure you that, if PDD becomes obligated to indemnify us for any substantial obligations, PDD will have the ability to do so. There also can be no assurance that we will be able to satisfy any indemnification obligations to PDD. Any failure by PDD to satisfy its obligations and any required payment by us could have a material adverse effect on our business.

Enacted and proposed changes in securities laws and regulations have increased our costs and may continue to increase our costs in the future. In recent years, there have been several changes in laws, rules, regulations and standards relating to corporate governance and public disclosure, including the Dodd-Frank Wall Street Reform and Consumer Protection Act (the “Dodd-Frank Act”), the Sarbanes-Oxley Act of 2002 (“Sarbanes-Oxley”) and various other new regulations promulgated by the SEC and rules promulgated by the national securities exchanges.

The Dodd-Frank Act, enacted in July 2010, expands federal regulation of corporate governance matters and imposes requirements on publicly-held companies, including us, to, among other things, provide stockholders with a periodic advisory vote on executive compensation and also adds compensation committee reforms and enhanced pay-for-performance disclosures. While some provisions of the Dodd-Frank Act are effective upon enactment, others will be implemented upon the SEC's adoption of related rules and regulations. The scope and timing of the adoption of such rules and regulations is uncertain and accordingly, the cost of compliance with the Dodd-Frank Act is also uncertain.

Sarbanes-Oxley required changes in some of our corporate governance and securities disclosure and compliance practices. Under Sarbanes-Oxley, publicly-held companies, including us, are required to, among other things, furnish independent annual audit reports regarding the existence and reliability of their internal control over financial reporting and have their chief executive officer and chief financial officer certify as to the accuracy and completeness of their financial reports.

These and other new or changed laws, rules, regulations and standards are, or will be, subject to varying interpretations in many cases due to their lack of specificity. As a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies, which could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. Our efforts to comply with evolving laws, regulations and standards are likely to continue to result in increased general and administrative expenses and a diversion of management time and attention from revenue-generating activities to compliance activities. Further, compliance with new and existing laws, rules, regulations and standards may make it more difficult and expensive for us to maintain director and officer liability insurance, and we may be required to accept reduced coverage or incur substantially higher costs to obtain coverage. Members of our board of directors and our principal executive officer and principal financial officer could face an increased risk of personal liability in connection with the performance of their duties. As a result, we may have difficulty attracting and retaining qualified directors and executive officers, which could harm our business. We continually evaluate and monitor regulatory developments and cannot estimate the timing or magnitude of additional costs we may incur as a result.

Our business, financial condition and results of operations may be adversely impacted by fluctuations in foreign currency exchange rates. Our international sales generally are denominated in local currencies. Fluctuations in the value of currencies in which we conduct business relative to the U.S. dollar result in currency transaction gains and losses, and the impact of future exchange rate fluctuations cannot be accurately predicted. Future fluctuations in currency exchange rates may have a material adverse impact on revenue from international sales, and thus on our business, financial condition and results of operations. When deemed appropriate, we may engage in currency exchange rate hedging transactions in an attempt to mitigate the impact of adverse exchange rate fluctuations. However, currency hedging policies may not be successful, and they may increase the negative impact of exchange rate fluctuations.

If we consume cash more quickly than expected, we may be unable to raise additional capital and we may be forced to curtail operations. We anticipate that our existing capital resources will be adequate to fund our operations for at least the next twelve months. However, our capital requirements will depend on many factors, including potential acquisitions of other businesses or technologies. If we determine that we must raise additional capital, we may attempt to do so through public or private financings involving debt or equity. However, additional capital may not be available on favorable terms, or at all. If adequate funds are not available, we may be required to curtail operations significantly or to obtain funds by entering into arrangements with collaborative partners or others that may require us to relinquish rights to certain of our technologies, products or potential markets that we would not otherwise relinquish.

Certain Risks Related to Owning Our Stock

We expect that our stock price will fluctuate significantly, and as a result, our stockholders may not be able to resell their shares at or above their original investment price. The stock market, historically and in recent years, has experienced significant volatility particularly with technology company stocks. The volatility of technology company stock prices often does not relate to the operating performance of the companies represented by the stock. Factors that could cause volatility in the price of our common stock include without limitation:


•	actual and anticipated fluctuations in our quarterly financial and operating results;


•	market conditions in the technology and software sectors;


•	issuance of new or changed securities analysts’ reports or recommendations;


•	developments or disputes concerning our intellectual property or other proprietary rights or other legal claims;


•	introduction of technological innovations or new commercial products by us or our competitors;


•	market acceptance of our products and services;


•	additions or departures of key personnel; and


•	the acquisition of new businesses or technologies

These and other external factors may cause the market price and demand for our common stock to fluctuate substantially, which may limit or prevent investors from readily selling their shares of common stock and may otherwise negatively affect the liquidity of our common stock.

As institutions hold the majority of our common stock in large blocks, substantial sales by these stockholders could depress the market price for our shares. As of February 24, 2014, the top ten institutional holders of our common stock held approximately 61% of our outstanding common stock. As a result, if one or more of these major stockholders were to sell all or a portion of their holdings, or if the market were to perceive that such sale or sales may occur, the market price of our common stock may fall significantly.

Because we do not intend to pay dividends, our stockholders will benefit from an investment in our common stock only if our stock price appreciates in value. We have never declared or paid any cash dividends on our common stock. We currently intend to retain our future earnings, if any, to finance the expansion of our business and do not expect to pay any cash dividends in the foreseeable future. As a result, the success of an investment in our common stock will depend entirely upon any future appreciation in its value. There is no guarantee that our common stock will appreciate in value or even maintain the price at which it was purchased.

Anti-takeover provisions under the DGCL and provisions in our certificate of incorporation and bylaws may make the accomplishment of mergers or the assumption of control by a principal stockholder more difficult, thereby making the removal of management more difficult. Certain provisions of the DGCL may delay or deter attempts to secure control of our company without the consent of our management. Also, our governing documents provide for a staggered board of directors, which will make it more difficult for a potential acquirer to gain control of our board of directors. These provisions of our governing documents and those of Delaware law could have the effect of delaying, deferring or preventing a change of control, including without limitation a proxy contest, making the acquisition of a substantial block of our common stock more difficult. The provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock. Further, the existence of these anti-takeover measures may cause potential bidders to look elsewhere, rather than initiating acquisition discussions with us.

Certain Risks Related to Intellectual Property

We may not be able to protect adequately the trade secrets and confidential information that we disclose to our employees. We rely upon trade secrets, technical know-how and continuing technological innovation to develop and maintain our competitive position. Competitors through their independent discovery (or improper means, such as unauthorized disclosure or industrial espionage) may come to know our proprietary information. We generally require employees and consultants to execute confidentiality and assignment-of-inventions agreements. These agreements typically provide that all materials and confidential information developed by or made known to the employee or consultant during his, her or its relationship with us are to be kept confidential, and that all inventions arising out of the employee's or consultant's relationship with us are our exclusive property. Our employees and consultants may breach these agreements, and in some instances we may not have an adequate remedy. Additionally, in some instances, we may have failed to require that employees and consultants execute confidentiality and assignment-of-inventions agreements.

Foreign laws may not afford us sufficient protections for our intellectual property, and we may not seek patent protection outside the U.S. We believe that our success depends, in part, upon our ability to protect our intellectual property throughout the world. However, the laws of some foreign countries may not be as comprehensive as those of the U.S. and may not be sufficient to protect our proprietary rights abroad. In addition, we generally do not pursue patent protection outside the U.S. because of cost and confidentiality concerns. Accordingly, our international competitors could obtain foreign patent protection for, and market overseas, products and technologies for which we are seeking patent protection in the U.S.

A patent issued to us may not be sufficiently broad to protect adequately our rights in intellectual property to which the patent relates. Due to cost and other considerations, we generally do not rely on patent protection to enforce our intellectual property rights, and have filed only a limited number of patent applications. Even if patents are issued to us, these patents may not sufficiently protect our interest in our software or other technologies because the scope of protection provided by any patents issued to or licensed by us are subject to the uncertainty inherent in patent law. Third parties may be able to design around these patents or develop unique products providing effects similar to our products. In addition, others may discover uses for our software or technologies other than those uses covered in our patents, and these other uses may be separately patentable. A number of pharmaceutical and biotechnology companies, software organizations and research and academic institutions, have developed technologies, filed patent applications or received patents on various technologies that may be related to our business. Some of these technologies, patent applications or patents may conflict with our technologies, patent applications or patents. These conflicts could also limit the scope of patents, if any, that we may be able to obtain, or result in the denial of our patent applications.

We may be subject to claims of infringement by third parties. A number of patents may have been issued or may be issued in the future that could cover certain aspects of our technology or functionality of our products and could prevent us from using technology that we use or expect to use, or making or selling certain of our products. In addition, to the extent our employees are involved in research areas similar to those areas in which they were involved at their former employers, we may inadvertently use or disclose alleged trade secrets or other proprietary information of their former employer. Thus, our products may infringe patent or other intellectual property rights of third parties, and we may be subject to infringement claims by third parties. Any such claims, with or without merit, could be time consuming to defend, result in costly litigation, divert management's attention and resources, cause product shipment delays or require us to enter into royalty or licensing agreements. Such licenses may not be available on terms acceptable to us, if at all. In the event of a successful claim of product infringement against us, our failure or inability to license or design around the infringed technology could have a material adverse effect on our business, financial condition and results of operations.

Third party software codes incorporated into our products could subject us to liability or limit our ability to sell such products. Some of our products include software codes licensed from third parties, including the open source community. Some of these licenses impose certain obligations upon us, including royalty and indemnification obligations. In the case of codes licensed from the open source community, the licenses may also limit our ability to sell products containing such code. Though we generally review the applicable licenses prior to incorporating third party code into our software products, there can be no assurance that such third party codes incorporated into our products would not subject us to liability or limit our ability to sell the products containing such code, thereby having a material adverse effect upon our business.



Item 1B.	Unresolved Staff Comments

None



Item 2.	Properties

The following is a summary of our principal business locations:



Location	Principal activities	Lease Ends	Square Feet
U.S.
San Diego, California,	Corporate headquarters, sales, customer support, marketing, product development and administration	2023	61,430
San Ramon, California	Product development, customer support, sales, marketing and administration	2016	64,409*
Bend, Oregon	Customer support, product development and marketing	2014	7,292
Bedminster, New Jersey	Customer support	2015	7,855
Jersey City, New Jersey	Sales	2016	3,250
Burlington, Massachusetts	Sales	2016	4,830
Milford, Massachusetts	Customer support, product development, sales and marketing	2019	19,556
Lafayette, Colorado	Customer support, product development and sales	2014	8,309
Durham, North Carolina	Product development, sales and marketing	2018	4,015

Europe
Cambridge, U.K.	Sales, customer support, marketing, product development and administration (EMEA Headquarters)	2022	24,451
Cork, Ireland	Sales, customer support, marketing, product development and administration (Qumas)	2014	7,500
Paris, France	Sales	2015	2,486
Liestal, Switzerland	Sales, customer support	2014	8,148
Cologne, Germany	Sales, customer support	2014	2,325
Stockholm, Sweden	Customer support	2014	3,014
Asia
Tokyo, Japan	Sales, customer support and administration (APAC Headquarters)	2014	9,001
Bangalore, India	Sales	2014	2,500

*15,734 square feet are sublet and 20,492 square feet are restructured.

We believe our existing properties are in good condition and are adequate to meet our current and reasonably foreseeable future requirements.



Item 3.	Legal Proceedings

Borealis Settlement

In July 2012, Symyx and Symyx Solutions, Inc. (collectively, the “Symyx Parties” ), each a wholly owned subsidiary we acquired in 2010, received a request for arbitration from Borealis AG ( “Borealis” ), a customer of the Symyx Parties, and on October 5, 2012, Borealis served us with its Statement of Case in connection with the arbitration, which is pending before the London Court of International Arbitration. The dispute related to certain software and professional services arrangements that Borealis claimed were not completed by the Symyx Parties pursuant to the terms of the underlying agreements during periods prior to our acquisition of the Symyx Parties.

On December 20, 2013, we entered into a settlement agreement (the “Settlement Agreement”) with Borealis in connection with the arbitration. Pursuant to the Settlement Agreement, (i) each party agreed to release all Claims (as defined in the Settlement Agreement) against the other party, in each case without any admission of liability to the other, (ii) the Symyx Parties agreed to make a one-time settlement payment, net of any tax withholding, to Borealis of $16.0 million (the “Settlement Payment”), and (iii) the parties agreed to take all actions necessary to obtain dismissal of the arbitration. We had previously accrued a reserve of approximately $10 million and received insurance proceeds relating to the Settlement Payment for approximately the same amount thereby resulting in a total net out of pocket payment by us of $5.9 million related to the Settlement Payment. Accordingly, we reversed any excess accrual upon receipt of insurance proceeds in the fourth quarter of 2013. All amounts incurred in connection with these matters have been recorded in the “Business consolidation, restructuring and headquarter-relocation costs” line in the accompanying consolidated statements of operations.

Transaction Litigation

On February 6, 2014, a putative class action lawsuit was filed in the Court of Chancery of the State of Delaware on behalf of our stockholders challenging the proposed Transactions. The lawsuit names us, the members of our board of directors, DSAC and Purchaser as defendants. The complaint generally alleges, among other things, that the members of our board of directors breached their fiduciary duties to our stockholders in connection with the Transactions by undertaking a flawed process that failed to maximize stockholder value, and that DSAC and Purchaser aided and abetted the alleged breach of fiduciary duties. The complaint seeks, among other things, (i) preliminary and permanent injunctive relief enjoining the defendants from consummating the Transactions pursuant to the terms of the Merger Agreement, (ii) damages and (iii) recovery of attorneys’ fees and other fees and costs. On February 24, 2014, the plaintiff in this lawsuit filed an amended complaint to include allegations that our officers and directors have interests in Transactions that conflict with the best interests of our stockholders and that our Solicitation/Recommendation Statement on Schedule 14D-9 (as may be amended and supplemented from time to time, the “Schedule 14D-9”), filed with the SEC on February 13, 2014, contains materially incomplete and misleading disclosures.

On February 21, 2014, a second putative class action lawsuit was filed in the Court of Chancery of the State of Delaware on behalf of our stockholders, challenging the proposed Transactions. The lawsuit names us, the members of our board of directors, Dassault Systèmes SA, DSAC and Purchaser as defendants. The complaint generally alleges, among other things, that the members of our board of directors breached their fiduciary duties to our stockholders in connection with the proposed Transactions by facilitating the acquisition of Accelrys for inadequate consideration and through a flawed sales process, agreeing to unfair deal protection devices that will preclude other bidders from making competing offers and misrepresenting and failing to disclose in the Schedule 14D-9 material information necessary for our stockholders to decide whether to tender their Accelrys common stock pursuant to the Offer or seek appraisal. The complaint further alleges that the other defendants aided and abetted the alleged breach of fiduciary duties. The complaint seeks, among other things, (i) injunctive relief enjoining the defendants from consummating the Transactions pursuant to the terms of the Merger Agreement, (ii) injunctive relief enjoining the Merger Agreement as invalid and unenforceable, or in the alternative, amending or enjoining the deal protection provisions of the Merger Agreement as necessary to ensure a full and fair sales process for the benefit of the plaintiffs, and unless or until the defendants disclose all material information to our stockholders, (iii) damages, (iv) imposition of a constructive trust in favor of the plaintiffs with respect to any benefits improperly received by the defendants as a result of their alleged wrongdoing and (v) recovery of attorneys’ fees and other fees and costs.

If the plaintiffs are successful in obtaining the injunctive relief sought, we may be unable to consummate the Transactions pursuant to the terms of the Merger Agreement in the expected timeframe, or at all. We, our board of directors, Dassault Systèmes SA, DSAC and Purchaser believe the respective allegations against them in the complaints are wholly without merit, and we each intend to vigorously defend against those allegations.

Other Claims and Legal Proceedings

We are also subject to various other claims and legal proceedings arising in the ordinary course of our business. In connection with our regular assessments of such other claims and legal proceedings, we accrue an estimated loss contingency in our financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. However, a determination as to the amount of the accrual required for such contingencies is highly subjective and requires judgments about future events. As a result, the amount of ultimate loss, if any, may differ from our estimates. Management believes that the disposition of other claims and legal proceedings arising in the ordinary course of our business, in the aggregate, will not have a material adverse effect on our results of operations, liquidity or financial position.



Item 4.	Mine Safety Disclosures

Not applicable.

PART II



Item 5.	Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Market for Common Stock

Our common stock trades on the NASDAQ Global Select Market under the symbol “ACCL”. The following table sets forth, for the periods indicated, the range of high and low sale prices per share of our common stock:



	High		Low
Year Ended December 31, 2013
First Quarter	$	9.86	$	9.19
Second Quarter	$	9.91	$	7.98
Third Quarter	$	9.98	$	8.38
Fourth Quarter	$	9.86	$	8.84
Year Ended December 31, 2012
First Quarter	$	8.45	$	6.43
Second Quarter	$	8.31	$	7.44
Third Quarter	$	8.91	$	7.59
Fourth Quarter	$	9.59	$	8.45

From the date of our initial public offering on December 5, 1995 until February 26, 2004, our stock traded under the symbol “PCOP”. Since February 27, 2004, our common stock has traded under the symbol “ACCL”.

Holders of Record

As of February 24, 2014 there were 303 holders of record of our common stock.

Dividends

No cash dividends have been paid on the common stock to date, nor do we anticipate paying dividends in the foreseeable future.

Equity Compensation Plan Information

The information required by Item 201(d) of Regulation S-K will be included in the definitive proxy statement for our 2012 annual meeting of stockholders or an amendment to this Report (either of the foregoing, a “Subsequent Filing”) to be filed with the SEC within 120 days after our fiscal period ended December 31, 2013 and is incorporated into this Report by reference.

Issuer Purchases of Equity Securities

The following table sets forth information concerning purchases of our common stock during the fourth quarter of the fiscal year ended December 31, 2013, which upon repurchase are classified as treasury shares available for general corporate purposes:



Period (1)	Total number of shares purchased	Average price paid per share	Total number of shares purchased as part of publicly announced plans or programs	Approximate dollar value of shares that may yet be purchased under the plans or programs
				(In thousands)
10/1/2013-10/31/2013	129,921	9.56	129,921	$	2,472
11/1/2013-11/30/2013	122,700	9.36	122,700	$	1,234
12/1/2013-12/31/2013	150,100	9.14	150,100	$	—

(1) On December 13, 2012, we entered into a stock repurchase plan in accordance with Rule 10b5-1 of the Exchange Act, instructing our broker, subject to the conditions set forth therein and the provisions of Rule 10b-18 of the Exchange Act, to purchase for our account up to $15.0 million worth of our common stock by December 31, 2013.

Comparison of Stockholder Return

The following information shall not be deemed to be “filed” with the SEC nor shall this information be incorporated by reference into any future filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that we specifically incorporate it by reference into a filing.

The following graph compares the five-year cumulative total return through December 31, 2013 for our common stock, which is traded under the symbol “ACCL” on the NASDAQ Global Select Market, to a broad market index, namely the NASDAQ U.S. Composite Index (the “NASDAQ Index”) and an industry index, namely the NASDAQ Computer and Data Processing Services Index (the “Industry Index”). This graph assumes an investment of $100 was made in both our common stock and in each index on March 31, 2009 and further assumes that all dividends were reinvested. The stock price performance on the graph is not necessarily indicative of future stock price performance.



	Accelrys, Inc.	NASDAQ Index	Industry Index
March 31, 2009	100.00	100.00	100.00
March 31, 2010	154.77	156.86	158.86
December 31, 2010	208.54	175.67	179.52
December 31, 2011	168.84	176.60	173.99
December 31, 2012	227.39	208.93	198.22
December 31, 2013	239.70	291.01	285.43



Item 6.	Selected Consolidated Financial Data

Change in Fiscal Year End

On August 3, 2010, our board of directors approved a change in our fiscal year end from March 31 to December 31. The fiscal year end change was effective December 31, 2010 and resulted in a nine-month reporting period from April 1, 2010 to December 31, 2010, which is included in the accompanying consolidated financial statements. All references to “years,” unless otherwise noted, refer to the twelve-month fiscal year, which prior to April 1, 2010, ended on March 31, and beginning with January 1, 2011, ends on December 31, of each year.

The following selected consolidated financial data have been derived from our audited consolidated financial statements. This data should be read in conjunction with “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our consolidated financial statements and related notes thereto included elsewhere in this Report. The following table sets forth our selected consolidated financial data as of and for the years ended December 31, 2013, December 31, 2012 and 2011, the nine months ended December 31, 2010 and the years ended March 31, 2010 and 2009.



	For the Years Ended									For the Nine Months Ended			For the Year Ended
	December 31, 2013			December 31, 2012			December 31, 2011			December 31, 2010			March 31, 2010

Consolidated Statements of Operations:
Revenue:
License and subscription revenue	$	86,393		$	89,440		$	79,425		$	51,003		$	64,854
Maintenance on perpetual licenses	40,196			38,254			34,862			12,512			10,499
Content	9,864			12,485			16,838			6,592			—
Professional services and other	32,073			22,347			13,214			10,098			7,606
Total revenue	168,526			162,526			144,339			80,205			82,959
Cost of revenue:
Cost of revenue	44,791			41,695			36,065			23,528			14,136
Amortization of completed technology	9,576			8,843			8,393			4,887			844
Total cost of revenue	54,367			50,538			44,458			28,415			14,980
Gross profit	114,159			111,988			99,881			51,790			67,979
Operating expenses:
Product development	37,477			38,849			33,977			22,080			16,045
Sales and marketing	60,786			57,971			51,517			34,848			38,042
General and administrative	16,503			17,480			16,467			11,697			12,479
Business consolidation, transaction and headquarter-relocation costs (recoveries)	15,477			7,803			7,775			16,493			(86		)
Note Receivable Impairment	1,663			—			—			—			—
Purchased intangible asset amortization	10,310			8,939			9,846			2,712			—
Total operating expenses	142,216			131,042			119,582			87,830			66,480
Operating loss	(28,057		)	(19,054		)	(19,701		)	(36,040		)	1,499



Net gain on sale of intellectual property	25,895			—			—			—			—
Net gain on sale of cost method investment	—			—			18,970			—			—
Royalty and other income, net	6,356			8,870			1,740			1,377			914
Income (loss) before income taxes	4,194			(10,184		)	1,009			(34,663		)	2,413
Income tax expense (benefit)	(1,496		)	218			(756		)	(14,055		)	1,218
Net income (loss)	$	5,690		$	(10,402	)	$	1,765		$	(20,608	)	$	1,195
Net income (loss) per share amounts:
Basic	$	0.10		$	(0.19	)	$	0.03		$	(0.44	)	$	0.04
Diluted	$	0.10		$	(0.19	)	$	0.03		$	(0.44	)	$	0.04

Weighted average shares used to compute net income (loss) per share:
Basic	55,686			55,696			55,489			46,446			27,504
Diluted	57,061			55,696			56,037			46,446			27,760

	December 31, 2013			December 31, 2012			December 31, 2011			December 31, 2010			March 31, 2010
Consolidated Balance Sheet Data:
Cash, cash equivalents, marketable securities and restricted cash	$	66,903		$	115,646		$	143,624		$	141,052		$	93,082
Promissory note receivable	7,393			34,796			34,720			—			—
Total assets	392,566			405,842			407,886			363,282			171,205
Total deferred revenue	85,617			89,151			86,012			67,459			61,325
Deferred gain on sale of intellectual property	—			25,895			25,974			—			—
Noncurrent liabilities(1)	26,351			10,098			10,634			11,331			6,953
Accumulated deficit	(247,597		)	(238,240		)	(198,208		)	(199,973		)	(179,365		)
Total stockholders’ equity	248,459			242,821			248,684			247,646			86,104


(1)	Noncurrent liabilities primarily consist of long-term, lease-related liabilities and accrued income tax and excludes deferred revenue amounts included in total deferred revenue.



Item 7.	Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with “Selected Consolidated Financial Data” and our consolidated financial statements and related notes thereto included elsewhere in this Report.

In addition to historical information, the following discussion contains forward-looking statements that are subject to certain risks and uncertainties, including those risks and uncertainties described in Item 1A of this Report. Actual results may differ substantially from those referred to herein due to a number of factors, including but not limited to those risks and uncertainties.

Overview

On July 1, 2010, pursuant to the terms of the Merger Agreement, by and among us, Symyx Merger Sub and Symyx , Symyx Merger Sub merged with and into Symyx, with Symyx surviving as our wholly owned subsidiary. Symyx's operating results are included in our consolidated financial statements and results of operations beginning July 1, 2010.

On May 19, 2011, we completed the Contur Acquisition, whereby Contur became our wholly owned subsidiary. Contur's operating results are included in our consolidated financial statements and results of operations beginning May 19, 2011.

On December 30, 2011, we completed the Velquest Acquisition, whereby VelQuest became our wholly owned subsidiary. VelQuest's operating results are included in our consolidated financial statements and results of operations beginning December 30, 2011.

On May 17, 2012, we acquired the HEOS software platform from Scynexis, Inc. The operating results of the HEOS platform are included in our consolidated financial statements and results of operations beginning May 17, 2012.

On October 23, 2012, we completed the Aegis Acquisition, whereby Aegis became our wholly owned subsidiary. Aegis's operating results are included in our consolidated financial statements and results of operations beginning October 23, 2012.

On January 11, 2013, we completed the Vialis acquisition, whereby Vialis became our wholly owned subsidiary. Vialis’ operating results are included in our consolidated financial statements and results of operations beginning January 11, 2013.

On September 3, 2013, we completed the ChemSW Acquisition, whereby ChemSW became our wholly owned subsidiary. ChemSW’s operating results are included in our consolidated financial statements and results of operations beginning September 3, 2013.

On December 9, 2013, we completed the Qumas Acquisition, whereby Qumas became our wholly owned subsidiary. Qumas’ operating results are included in our consolidated financial statements and results of operations beginning December 9, 2013.

Recent Developments

Our Business

As the leading provider of scientific innovation lifecycle management software, we develop and commercialize informatics software products and services for industries and organizations that rely on scientific innovation to differentiate themselves in the marketplace, with a particular emphasis on pharmaceutical, biotechnology, energy, chemicals, food and beverage and consumer packaged goods companies. The Accelrys Enterprise Platform provides a broad, flexible science-based foundation optimized to integrate the diversity of science, experimental processes and information requirements across the research, development, process scale-up and manufacturing phases of product development. Our software applications for Modeling and Simulation, Research Informatics, Laboratory Informatics, Enterprise Quality Management, Environmental Health & Safety and Operations Intelligence enable innovators to access, organize, analyze and share data in unprecedented ways, ultimately enhancing innovation, improving productivity, reducing compliance risk, lowering costs, enhancing sustainability and accelerating products from lab to market. Additionally, our software manages and connects scientific

innovation processes and information with other lifecycle systems including Enterprise Resource Planning (ERP) and Product Lifecycle Management (PLM) systems.

Our acquisitions over the past two years have been critical initiatives in increasing the breadth and depth of our product portfolio by extending our offerings beyond research and into development and manufacturing with a view to covering the end-to-end product lifecycle.

The Aegis Acquisition expanded our portfolio into downstream operations with new solutions supporting Operations Intelligence in enterprise manufacturing. In addition, the Vialis Acquisition has added system integration capabilities that have strengthened our position in the Laboratory Informatics market with added capabilities in the downstream analytical development, quality control and quality assurance and manufacturing areas. The ChemSW Acquisition has enabled us to provide solutions for managing and tracking the source, use and disposal of chemicals along the entire lab-to-plant value chain. The Qumas Acquisition has further extended our informatics portfolio with the addition of proven, mission-critical, end-to-end document and process management compliance solutions.

Description of Our Markets and Business

The pharmaceutical and biotechnology industries are a very important part of our business. Our products have been widely adopted within the research functions of businesses in these industries and are gaining increased traction in the development, QA/QC and manufacturing functions of such businesses. However, these markets present challenges due to industry consolidation, market maturity, patent expirations, reduced discovery research activity, increased competition, including competition from open source software, and outsourcing of research to other entities. The other industries we serve, including energy, chemicals, food and beverage, and consumer packaged goods, are earlier in the adoption curve for such scientific software products but are increasingly investigating their value, which we view as both a challenge and an opportunity.

Business Strategy

Our strategy is to partner with customers to optimize their scientific innovation lifecycle management from discovery through commercialization. Consequently, we are extending beyond our historically strong presence in research downstream to offer customers an integrated portfolio of software and services addressing the entire product lifecycle. This means moving into new domains, including biology; and expanding our presence outside of the pharmaceutical and biotech industries into other key industries such as energy, chemicals, food and beverage and consumer packaged goods companies. We do this by addressing the core challenges faced by R&D and quality organizations, offering them an open enterprise-scale scientific software platform and a broad portfolio of software applications leveraging our deep domain expertise in chemistry, biology and the materials sciences. We believe the combination of the Accelrys Enterprise Platform with its Component Collections and associated set of applications and services including the Accelrys Pipeline Pilot authoring application and software capabilities in Modeling and Simulation, Research Informatics, Laboratory Informatics, Enterprise Quality Management, Environmental Health & Safety and Operations help optimize the scientific innovation lifecycles of our customers. Additionally, our software manages and connects scientific processes and information with other lifecycle systems, including Enterprise Resource Planning (ERP) and Product Lifecycle Management (PLM) systems.

The new products and domain expertise we have gained as a result of our acquisitions over the past two years, including QUMAS, ChemSW, Vialis and Aegis, provide greater value to the development, QA/QC and manufacturing functions of our customer organizations. Our plan is to continue to integrate and augment these offerings to further enhance the value of the products and expertise we acquired and our overall product portfolio. The combined Qumas and Accelrys product portfolios provide the industry’s only complete solution supporting quality and regulatory compliance across the product lifecycle, from product ideation through R&D to quality, manufacturing and supply chain. The integration of ChemSW’s inventory management software into Accelrys' robust enterprise platform enables our combined customer base to comply with challenging global, national and local environmental health & safety regulations. The Aegis Acquisition further expands our downstream footprint with Accelrys Discoverant, the industry-leading Operations Intelligence software solution.

Critical Accounting Policies

Our discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the U.S. (“GAAP”). The preparation of the consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and the related disclosure of contingent assets and liabilities. We review our estimates on an on-going basis, including those related to income taxes and the valuation of goodwill, intangibles and other long-lived assets. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions. Our accounting

policies are described in more detail in Note 1 to our consolidated financial statements included elsewhere in this Report. We have identified the following as the most critical accounting policies and estimates used in the preparation of our consolidated financial statements.

Revenue Recognition

We generate revenue from the following primary sources:


•	software licenses,


•	post-contract customer support and maintenance services on licensed software (collectively referred to as “PCS”),


•	content, and


•	professional services.

Customer billings issued in connection with our revenue-generating activities are initially recorded as deferred revenue. We then recognize the revenue from these customer billings as set forth below and when all of the following criteria are met:


•	a fully executed written contract or purchase order has been obtained from the customer (i.e., persuasive evidence of an arrangement exists),


•	the contractual price of the product or service has been defined and agreed to in the contract or purchase order (i.e., price is fixed or determinable),


•	delivery of the product or service has occurred and no material uncertainties regarding customer acceptance of the delivered product or service exist, and


•	collection of the purchase price from the customer is considered probable.

Software Licenses. We license software on a term and perpetual basis. When sold perpetually, our standard perpetual software licensing arrangements generally include twelve months of bundled PCS, while our standard term-based software licensing arrangements typically include PCS for the full duration of the term license. In limited cases, multi-year term licenses (generally ranging from two to three years) are sold in conjunction with twelve months of maintenance. In relation to arrangements including products for which we have established vendor-specific objective evidence (“VSOE”) of selling price of the related undelivered elements, we recognize the software licensing revenue upon delivery, after any required re-allocation, assuming all other revenue recognition criteria have been satisfied. For the majority of the license revenues we sell we have concluded that we do not have VSOE. For the products where VSOE of selling price does not exist, the entire fee for perpetual and term-based licenses are generally recognized ratably over the contractual term of the bundled PCS. In addition, certain provisions, such as mandatory PCS or product remix rights that do not qualify as exchange accounting, preclude upfront recognition of the software license revenue. In such cases, the arrangements are considered in substance subscriptions and all contractual fees are recognized over the contractually stated PCS period.

Renewal of PCS Under Perpetual Software Licenses. Our PCS includes the right to receive unspecified upgrades or enhancements and technical support. Fees from customer renewals of PCS related to previously purchased perpetual licenses are recognized ratably over the term of the PCS when sold as a multiple element arrangement.

Content. Content is licensed on a term basis and provides customers with access to the licensed content over the term of the agreement. Revenue from these licensing arrangements is recognized ratably over the term of the agreement, which is typically twelve months and coincides with the term of the PCS and/or licensed software.

Professional Services. We provide certain services to our customers, including non-complex product training, installation, implementation and other professional services which are non-essential to the operation of the software. We also perform professional services for our customers designed to enhance the value of our software products by creating extensions to functionality to address a client's specific business needs. When sold separately, revenue from time and materials service engagements are generally recognized as the services are performed. Revenue from fixed fee service engagements is recognized as the services are performed using the percentage-of-completion method when we can reasonably estimate the level of effort required to complete our performance obligations under an arrangement and such performance obligations are provided on a best-efforts basis. For service arrangements that include provisions that create significant uncertainties (e.g., customer acceptance) or service deliverables wherein the level of effort to complete the services cannot be reasonably estimated, the associated revenue is recognized using the completed performance method.

Hosting Services. We are an application service provider (“ASP”), meaning we provide hosting services that give customers access to software that resides on our servers. The ASP model typically includes an up-front fee and a monthly commitment from the customer that commences upon completion of the implementation through the remainder of the customer life. The up-front fee is the initial setup fee, or the implementation fee. The monthly commitment includes, but is not limited to, a fixed monthly fee or a transactional fee based on system usage that exceeds monthly minimums. We do not view the signing

of the contract or the provision of initial setup services as discrete earnings events that have stand-alone value. Revenue is typically deferred until the date the customer commences use of our services, at which point the up-front fees are recognized ratably over the life of the customer arrangement.

Multi-Element Arrangements. For multi-element arrangements that include software licenses, PCS, and non-essential installation and implementation services, the entire fee for such arrangements is recognized as revenue ratably over the term of the PCS or delivery of the services, whichever is longer. For multi-element arrangements that also include services that are essential to the operation of the software, the fee for such arrangements is generally deferred until the services essential to the operation of the software have been performed, at which point the entire fee for such arrangements is recognized as revenue ratably over the remaining term of the PCS or the delivery of the non-essential services, whichever is longer. For financial statement presentation purposes, we allocate the arrangement fee to the software-related elements and the non-software-related elements based upon the relative standard list price of the products and/or services that comprise each element, which is our best estimate of selling price.

Royalty Income

We recognize royalty income based on reported sales by third party licensees of products containing the applicable licensed materials and intellectual property. Royalty revenue is recognized as these payments become due. Non-refundable royalties, for which there are no further performance obligations, are recognized when due under the terms of the applicable agreements. Royalty income is included in the royalty and other income, net line on the consolidated statements of operations.

Goodwill and Purchased Intangible Assets

Our goodwill resulted from acquisitions in fiscal years 1999 through 2013. Goodwill and intangible assets with indefinite useful lives are not amortized, but are tested for impairment at least annually or as circumstances indicate that their value may no longer be recoverable. In accordance with ASC Topic 350, Intangibles—Goodwill and Other (“ASC Topic 350”), we review our goodwill and indefinite-lived intangible asset for impairment at least annually in our fiscal fourth quarter and more frequently if events or changes in circumstances occur that indicate a potential reduction in the fair value of our reporting unit and/or our indefinite-lived intangible asset below their respective carrying values. Examples of such events or circumstances include: a significant adverse change in legal factors or in the business climate, a significant decline in our stock price, a significant decline in our projected revenue or cash flows, an adverse action or assessment by a regulator, unanticipated competition, a loss of key personnel, or the presence of other indicators that would indicate a reduction in the fair value of a reporting unit.

Our goodwill is considered to be impaired if we determine that the carrying value of the reporting unit to which the goodwill has been assigned exceeds management’s estimate of its fair value. Based on the guidance provided by ASC Topic 350 and ASC Topic 280, Segment Reporting, (“ASC Topic 280”) management has determined that our company operates in one segment and consists of one reporting unit given the similarities in economic characteristics between our operations and the common nature of our products, services and customers. Because we have only one reporting unit, and because we are publicly traded, we determine the fair value of the reporting unit based on our market capitalization as we believe this represents the best evidence of fair value. In the fourth quarter of fiscal 2013, we completed our annual goodwill impairment test as of December 31, 2013 and concluded that our goodwill was not impaired. Our conclusion that goodwill was not impaired was based on a comparison of our net assets as of December 31, 2013 to our market capitalization.

Because we determine the fair value of our reporting unit based on our market capitalization, our future reviews of goodwill for impairment may be impacted by changes in the price of our common stock. For example, a significant decline in the price of our common stock may cause the fair value of our goodwill to fall below its carrying value. Therefore, we cannot assure you that when we complete our future reviews of goodwill for impairment a material impairment charge will not be recorded.

Valuation of Indefinite-Lived Intangible Asset

In connection with our acquisition of SciTegic in September 2004, we acquired the SciTegic trade name which was determined to be indefinitely lived. In accordance with ASC Topic 350, we review our indefinite-lived intangible asset for impairment at least annually in our fiscal fourth quarter and more frequently if events or changes in circumstances occur that indicate a potential reduction in the fair value of the asset below its carrying value. Examples of such events or circumstances include: a significant adverse change in legal factors or in the business climate, a significant decline in our stock price, a significant decline in our projected revenue or cash flows, an adverse action or assessment by a regulator, unanticipated competition, a loss of key personnel, or the presence of other indicators that would indicate a reduction in the fair value of an asset.

Our indefinite-lived intangible asset is considered to be impaired if we determine that the carrying value of the asset exceeds its estimated fair value. In the quarter ended December 31, 2013 we completed our annual indefinite-lived intangible asset impairment test as of December 31, 2013 and concluded that our indefinite-lived intangible asset was not impaired. We estimated the fair value of our indefinite-lived intangible asset utilizing a discounted cash flow analysis which considers the estimated future customer orders for our scientific informatics platform product line and the associated direct and incremental selling, marketing and development costs. Key assumptions included in the discounted cash flow analysis include projections of future customer order growth for our scientific informatics platform product line and developing an appropriate discount rate.

We cannot assure you that the underlying assumptions used to forecast the cash flows will materialize as estimated. For example, if our projections of future customer order growth do not materialize, the fair value of our indefinite-lived intangible asset may fall below its carrying value. Therefore, we cannot assure you that when we complete our future reviews of our indefinite-lived intangible asset for impairment that a material impairment charge will not be recorded.

Impairment of Long-Lived Assets

We review long-lived assets to be held and used, including acquired intangible assets subject to amortization and property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. Conditions that would necessitate an impairment assessment include a significant decline in the market price of an asset or asset group, a significant adverse change in the extent or manner in which an asset or asset group is being used, the loss of legal ownership or title to the asset, significant negative industry or economic trends or the presence of other indicators that would indicate that the carrying amount of an asset or asset group is not recoverable.

A long-lived asset is considered to be impaired if the estimated undiscounted future cash flows resulting from the use of the asset and its eventual disposition are not sufficient to recover the carrying value of the asset. In order to estimate an asset’s undiscounted future cash flows, we utilize our internal forecast of our future operating results and cash flows, our strategic business plans and anticipated future economic and market conditions. There are inherent estimates and assumptions underlying this information and management’s judgment is required in the application of this information to the determination of an asset’s undiscounted future cash flows. No assurance can be given that the underlying estimates and assumptions utilized in our determination of an asset’s undiscounted future cash flows will materialize as anticipated.

Valuation of Marketable Securities

We invest in various types of securities, including obligations of U.S. government sponsored enterprises, commercial paper, certificates of deposits, corporate and municipal debt. In accordance with the accounting standard for fair value measurements, we classify our investments as Level 1, 2 or 3 within the fair value hierarchy. Fair values determined by Level 1 inputs utilize quoted prices that are observable for the asset or liability, either directly or indirectly. Fair values determined by Level 2 inputs utilize data points that are observable, and have active markets, for the asset or liability, either directly or indirectly. These might include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by market data by correlation or other means. Fair values determined by Level 3 inputs utilize model-derived valuations in which one or more significant inputs or significant value-drivers are unobservable. As noted in note “6. Fair Value Measurements” in Part II, Item 8 of this Form 10-K, a majority of our security holdings have been classified as Level 2.

We assess our marketable securities for impairment under the guidance provided by ASC Topic 320, Investments—Debt and Equity Securities. Accordingly, we review the fair value of our marketable securities at least quarterly to determine if declines in the fair value of individual securities are other-than-temporary in nature. If we believe the decline in the fair value of an individual security is other-than-temporary, we write-down the carrying value of the security to its estimated fair value, with a corresponding charge against income. To determine if a decline in the fair value of an investment is other-than-temporary, we consider several factors including, among others, the period of time and extent to which the estimated fair value has been less than cost, overall market conditions, the historical and projected future financial condition of the issuer of the security and our ability and intent to hold the security for a period of time sufficient to allow for a recovery of the market value.

Long-Term Investments and Promissory Notes Receivable

Our long-term investments consist of equity investments in privately held companies. We determine the accounting method used to account for investments in equity securities of other business entities in which we do not have a controlling interest primarily based on our ownership of each such business entity and whether we have the ability to exercise significant influence over the strategic, operating, investing and financing activities of each such business entity. As we do not have a

controlling interest or have the ability to exercise significant influence over the companies in which we invest, we account for such investments using the cost method of accounting. We evaluate our investments for impairment in the quarter ended December 31 or whenever there are any events or circumstances that are likely to have a significant adverse effect on the fair value of the investment. In our impairment assessment we consider current factors, including economic environment, market conditions and operational performance, and other specific factors relating to the business underlying the investment. If the fair value of the investment is less than its carrying value we recognize an impairment loss equal to the difference between an investment’s carrying value and its fair value.

As a result of indicators of potential impairment identified in the fourth quarter of 2013, we performed an impairment assessment of our cost-method investment in Freeslate Inc. (“Freeslate”), a privately held company headquartered in Sunnyvale, California that designs, develops and deploys integrated workflows for research and development labs, and based on such assessment we determined that the Freeslate cost-method investment is not impaired. This determination was based upon a discounted cash flow model based upon future operating performance estimates, adjusted for the lack of marketability of the investment. As part of our assessment we performed a sensitivity analysis on our assumptions, primarily around the risk adjusted estimated future cash flows and the discount rate assumptions. Our sensitivity analysis includes several combinations of reasonably possible scenarios with regard to these assumptions and in no scenario was an impairment identified.

Promissory notes receivable are recorded at stated principal amount net of any discount or premium and allowance for uncollectibility. The related discounts or premiums are accreted or amortized over the life of the related note receivable and recorded in the "Royalty and other income" line in our consolidated statement of operations. Promissory notes receivable are not measured at fair value on a recurring basis, but are reviewed for possible impairment in the quarter ended December 31, 2013 or whenever events or changes in circumstances indicate that the carrying amount of the notes receivable may not be fully recoverable. In our evaluation of possible impairment, we determine the expected cash flow for the notes receivable based on the financial performance of the note holder, including consideration of estimated proceeds from the disposition of any collateral, and calculate an estimate of the potential loss and the probability of loss. For notes receivable where a loss is probable, we record a specific reserve.

As a result of indicators of impairment identified in the fourth quarter of 2013, we evaluated the recoverability of our Freeslate note receivable based on a discounted cash flow model and as a result of this analysis we established a reserve of $1.7 million through an impairment charge on the note receivable which is included in the consolidated statement of operations for the year ended December 31, 2013. In performing our impairment assessment, we utilized a discounted cash flow model considering the risk adjusted future financial performance of Freeslate and their ability to obtain operating capital over the remaining current contractual note term of 6.25 years and a discount rate of 11.0%. We performed a sensitivity analysis on our assumptions, primarily around the risk adjusted estimated future cash flows and the discount rate assumptions. Our sensitivity analysis includes several combinations of reasonably possible scenarios with regard to these assumptions. If we do not adjust the cash flows for the potential risk that expected cash flows will not materialize, the fair value of the note and related interest receivable is approximately $9.7 million and as such would not be considered impaired. While we believe that our analysis provides a reasonable basis on which to evaluate the recovery of our note receivable, other facts or circumstances may arise that could impact the impairment assessment including inherent estimates and assumptions used and while we believe that our analysis provides a reasonable basis on which to evaluate the recovery of our investment, other facts or circumstances may arise that could impact the impairment assessment and therefore our analysis should not be used as a sole predictor of impairment.

Valuation of Share-Based Awards

We account for our share-based awards in accordance with ASC Topic 718, Compensation—Stock Compensation (“ASC Topic 718”). We estimate the fair value of our share-based stock awards on the date of grant using the Black-Scholes option-pricing model. The Black-Scholes option-pricing model requires the use of certain input variables, as follows:

Expected Volatility. Volatility is a measure of the amount the stock price will fluctuate during the expected life of an award. We determine volatility based on our historical stock price volatility over the most recent period equivalent to the expected life of the award, giving consideration to company-specific events impacting our historical volatility that are unlikely to occur in the future, as well as anticipated future events that may impact volatility. We also consider the historical stock price volatilities of comparable publicly traded companies.

Risk-Free Interest Rate. Our assumption of the risk-free interest rate is based on the interest rates on U.S. constant rate treasury securities with contractual terms approximately equal to the expected life of the award.

Expected Dividend Yield. Because we have not paid any cash dividends since our inception and do not anticipate paying dividends in the foreseeable future, we assume a dividend yield of zero.

Expected Award Life. We determine the expected life of an award by considering various relevant factors, including the vesting period and contractual term of the award, our employees’ historical exercise patterns and length of service and employee characteristics. We also consider the expected award lives of comparable publicly traded companies. For stock purchase plan purchase rights, the expected life is equal to the current offering period under the stock purchase plan.

Under ASC Topic 718, we are also required to estimate at grant the likelihood that the award will ultimately vest (the “pre-vesting forfeiture rate”), and to revise the estimate, if necessary, in future periods if the actual forfeiture rate differs. We determine the pre-vesting forfeiture rate of an award based on our historical pre-vesting award forfeiture experience, giving consideration to company-specific events impacting historical pre-vesting award forfeiture experience that are unlikely to occur in the future as well as anticipated future events that may impact forfeiture rates.

Our determination of the input variables used in the Black-Scholes option pricing model as well as the pre-vesting forfeiture rate is based on various underlying estimates and assumptions that are highly subjective and are affected by our stock price, among other factors. Changes in these underlying estimates and assumptions could materially affect the fair value of our share-based awards and, therefore, the amount of share-based compensation expense to be recognized in our results of operations.

Income Taxes

We account for income taxes in accordance with ASC Topic 740, Income Taxes. Deferred tax assets and liabilities are recognized for the tax consequences of temporary differences between the financial carrying amounts and the tax basis of existing assets and liabilities by applying enacted statutory tax rates applicable to future years. The provision for income taxes is based on our estimates for taxable income of the various legal entities we operate and the various jurisdictions in which we operate. As such, income tax expense may vary from the customary relationship between income tax expense and pre-tax income. We establish a valuation allowance against our net deferred tax assets to reduce them to the amount expected to be realized.

We assess the recoverability of our deferred tax assets on an ongoing basis. In making this assessment we are required to consider all available positive and negative evidence to determine whether, based on such evidence, it is more likely than not that some portion or all of our net deferred assets will be realized in future periods. This assessment requires significant judgment. We do not recognize current and future tax benefits until it is more likely than not that our tax positions will be sustained. In general, any realization of our net deferred tax assets will reduce our effective rate in future periods. However, the realization of deferred tax assets that are related to NOLs that were generated by tax deductions resulting from the exercise of non-qualified stock options will be a direct increase to stockholders’ equity.

We determine whether the benefits of our tax positions are more-likely-than-not to be sustained upon audit based on the technical merits of the tax position. We recognize the impact of an uncertain income tax position taken on our income tax return at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position is not recognized if it has less than a 50% likelihood of being sustained.

Change in Fiscal Year and Comparative Financial Information

On August 3, 2010, our board of directors approved a change in our fiscal year end from March 31 to December 31. The fiscal year end change was effective December 31, 2010 and resulted in a nine-month reporting period from April 1, 2010 to December 31, 2010, which is included in the accompanying consolidated financial statements. All references to “years”, unless otherwise noted, refer to the twelve-month fiscal year, which prior to April 1, 2010, ended on March 31, and beginning with January 1, 2011, ends on December 31, of each year.

Results of Operations

The following table sets forth the consolidated statements of operations data for the periods presented (amounts in thousands, except per share data). Financial information for the years ended December 31, 2013, 2012 and 2011, respectively, was derived from audited financial statements.



	For the Years Ended
Consolidated Statements of Operations:	December 31, 2013			December 31, 2012			December 31, 2011
Revenue:
License and subscription revenue	$	86,393		$	89,440		$	79,425
Maintenance on perpetual licenses	40,196			38,254			34,862
Content	9,864			12,485			16,838
Professional services and other	32,073			22,347			13,214
Total revenue	168,526			162,526			144,339
Cost of revenue:
Cost of revenue	44,791			41,695			36,065
Amortization of completed technology	9,576			8,843			8,393
Total cost of revenue	54,367			50,538			44,458
Gross profit	114,159			111,988			99,881
Operating expenses:
Product development	37,477			38,849			33,977
Sales and marketing	60,786			57,971			51,517
General and administrative	16,503			17,480			16,467
Business consolidation, transaction and headquarter-relocation costs	15,477			7,803			7,775
Note Receivable Impairment	1,663			—			—
Purchased intangible asset amortization	10,310			8,939			9,846
Total operating expenses	142,216			131,042			119,582
Operating loss	(28,057		)	(19,054		)	(19,701		)
Net gain on sale of intellectual property	25,895			—			—
Net gain on sale of cost method investment	—			—			18,970
Royalty and other income, net	6,356			8,870			1,740
Income (loss) before income taxes	4,194			(10,184		)	1,009
Income tax expense (benefit)	(1,496		)	218			(756		)
Net income (loss)	$	5,690		$	(10,402	)	$	1,765

Net income (loss) per share amounts:
Basic	$	0.10		$	(0.19	)	$	0.03
Diluted	$	0.10		$	(0.19	)	$	0.03
Weighted average shares used to compute net income (loss) per share:
Basic	55,686			55,696			55,489
Diluted	57,061			55,696			56,037

Comparison of the Years Ended December 31, 2013, 2012 and 2011

The following table summarizes our results of operations as a percentage of revenue for the respective periods:



	For the Years Ended
	December 31, 2013		December 31, 2012		December 31, 2011
Revenue:
License and subscription revenue	51	%	55	%	55	%
Maintenance on perpetual licenses	24	%	24	%	24	%
Content	6	%	8	%	12	%
Professional services and other	19	%	14	%	9	%
Total revenue	100	%	100	%	100	%
Cost of revenue:
Cost of revenue	27	%	26	%	25	%
Amortization of completed technology	6	%	5	%	6	%
Total cost of revenue	32	%	31	%	31	%
Gross profit	68	%	69	%	69	%
Operating expenses:					—
Product development	22	%	24	%	24	%
Sales and marketing	36	%	36	%	36	%
General and administrative	10	%	11	%	11	%
Business consolidation, transaction and headquarter-relocation costs	9	%	5	%	5	%
Note Receivable Impairment	1	%	—	%	—	%
Purchased intangible asset amortization	6	%	6	%	7	%
Total operating expenses	84	%	81	%	83	%
Operating loss	(17	)%	(12	)%	(14	)%
Net gain on sale of intellectual property	15	%	—	%	—	%
Net gain on sale of cost method investment	—	%	—	%	13	%
Royalty and other income, net	4	%	5	%	1	%
Income (loss) before income taxes	2	%	(6	)%	1	%
Income tax expense (benefit)	(1	)%	—	%	(1	)%
Net income (loss)	3	%	(6	)%	1	%

Revenue



	For the Years Ended December 31
	2013		2012		2011		% Change 2013-2012		% Change 2012-2011
License and subscription revenue	$	86,393	$	89,440	$	79,425	(3	)%	13	%
Maintenance on perpetual licenses	40,196		38,254		34,862		5	%	10	%
Content	9,864		12,485		16,838		(21	)%	(26	)%
Professional services and other	32,073		22,347		13,214		44	%	69	%
Total revenue	$	168,526	$	162,526	$	144,339	4	%	13	%

Comparison of the Years Ended December 31, 2013 and 2012

Total revenue for the year ended December 31, 2013 increased to $168.5 million, or 4%, compared to the year ended December 31, 2012. The increase in total revenue during the year ended December 31, 2013 was attributable to incremental revenue from the Vialis Acquisition, the ChemSW Acquisition and the Qumas Acquisition, an increase in professional services revenue attributable to growth in services engagement orders, offset by the impact of a decrease in orders in fiscal 2013. Foreign currency also unfavorably impacted total revenue by approximately $7.2 million primarily from the Japanese Yen.

Total revenue generated in the U.S. accounted for $83.1 million, or 49% of revenue for the year ended December 31, 2013, as compared to $79.6 million, or 49% of revenue, for the year ended December 31, 2012. International revenue accounted for $85.4 million, or 51% of revenue, for the year ended December 31, 2013, as compared to $82.9 million, or 51% of revenue, for the year ended December 31, 2012.

License and Subscription Revenue. License and subscription revenue for year ended December 31, 2013 decreased to $86.4 million, or 3%, compared to the year ended December 31, 2012. The decrease in license and subscription revenue during the year ended December 31, 2013 was primarily attributable to a decrease in orders in fiscal 2013 combined with unfavorable foreign currency impact primarily in Japan, partially offset by increase in revenue from the Contur Acquisition and incremental revenue from the Qumas acquisition.

Maintenance on Perpetual Licenses. Maintenance on perpetual licenses for the year ended December 31, 2013 increased to $40.2 million, or 5%, compared to the year ended December 31, 2012. The increase in revenue from maintenance on perpetual licenses during the year ended December 31, 2013 was primarily related to incremental revenue from the Aegis Acquisition and the Contur Acquisition, offset by the impact of a decrease in orders in fiscal 2013 and unfavorable foreign currency impact primarily in Japan.

Content. Content revenue for the year ended December 31, 2013 decreased to $9.9 million, or 21%, compared to the year ended December 31, 2012. The decrease in content revenue during the year ended December 31, 2013 was attributable to the previously announced phase-out of certain content product lines.

Professional Services and Other. Professional services and other revenue for the year ended December 31, 2013 increased to $32.1 million, or 44%, compared to the year ended December 31, 2012. The increase in revenue from professional services and other during the year ended December 31, 2013 was primarily attributable to growth in services engagement orders.

Comparison of the Years Ended December 31, 2012 and 2011

Total revenue for the year ended December 31, 2012 increased to $162.5 million, or 13%, compared to the year ended December 31, 2011. The increase in total revenue during the year ended December 31, 2012 was attributable to a decrease in the impact of acquisition-related valuation adjustments on revenue recognition related to the Symyx Merger, combined with incremental revenue from the VelQuest Acquisition and the Contur Acquisition

Total revenue generated in the U.S. accounted for $79.6 million, or 49% of revenue for the year ended December 31, 2012, as compared to $67.8 million, or 47% of revenue, for the year ended December 31, 2011. International revenue accounted for $82.9 million, or 51% of revenue, for the year ended December 31, 2013, as compared to $76.6 million, or 53% of revenue, for the year ended December 31, 2011.

License and Subscription Revenue. License and subscription revenue for year ended December 31, 2012 increased to $89.4 million, or 13%, compared to the year ended December 31, 2011. The increase in license and subscription revenue during the year ended December 31, 2012 was primarily attributable to additional revenue resulting from the Contur Acquisition and the VelQuest Acquisition, combined with an incremental increase as a result of a decrease in revenue impacted by acquisition-related valuation adjustments related to the Symyx Merger.

Maintenance on Perpetual Licenses. Maintenance on perpetual licenses for the year ended December 31, 2012 increased to $38.3 million, or 10%, compared to the year ended December 31, 2011. The increase in revenue from maintenance on perpetual licenses during the year ended December 31, 2012 was primarily attributable to incremental revenue from the VelQuest Acquisition, combined with an incremental increase as a result of a decrease in revenue impacted by acquisition-related valuation adjustments related to the Symyx Merger.

Content. Content revenue for the year ended December 31, 2012 decreased to $12.5 million, or 26%, compared to the year ended December 31, 2011. The decrease in content revenue during the year ended December 31, 2012 was attributable to the previously announced phase-out of certain content product lines.

Professional Services and Other. Professional services and other revenue for the year ended December 31, 2012 increased to $22.3 million, or 69% , compared to the year ended December 31, 2011. The increase in revenue from professional services and other revenue during the year ended December 31, 2012 was primarily attributable to an increase in revenue from solution consulting and contract research engagements.

Total Cost of Revenue



	For the Years Ended December 31
	2013	2012	2011	% Change 2013-2012		% Change 2012-2011
Cost of revenue	44,791	41,695	36,065	7	%	16	%
Amortization of completed technology	9,576	8,843	8,393	8	%	5	%

Comparison of the Years Ended December 31, 2013 and 2012

Cost of Revenue. Cost of revenue for the year ended December 31, 2013 increased to $44.8 million, or 7% , compared to the year ended December 31, 2012. The increase in cost of revenue during the year ended December 31, 2013 was primarily attributable to an increase in personnel and related expenses in our services department of approximately $2.6 million from higher headcount associated with the Vialis Acquisition, the ChemSW Acquisition and the Qumas Acquisition, consulting and professional fees of approximately $1.0 million, overhead expense of approximately $0.5 million, software and distribution costs of $0.1 million and distributor commissions of approximately $0.6 million, partially offset by a an increase in capitalized labor costs of $1.8 million associated with the growth in professional services engagements.

Amortization of Completed Technology. Amortization of completed technology for the year ended December 31, 2013 increased to $9.6 million, or 8% , as compared to the year ended December 31, 2012. The increase in amortization of completed technology during both periods was attributable to an increase in intangible assets acquired in the Acquisitions.

Comparison of the Years Ended December 31, 2012 and 2011

Cost of Revenue. Cost of revenue for the year ended December 31, 2012 increased to $41.7 million, or 16% , compared to the year ended December 31, 2011. The increase in cost of revenue during the year ended December 31, 2012 was primarily attributable to increases in personnel and related expenses in our services department of approximately $4.2 million from higher headcount, consulting and professional fees of approximately $0.9 million, overhead expense of approximately $0.4 and capitalized labor costs of $0.6 million, partially offset by a decrease in software and content royalties of approximately $0.4 million and a decrease in distributor commissions of approximately $0.1 million.

Amortization of Completed Technology. Amortization of completed technology for the year ended December 31, 2012 increased to $8.8 million, or 5%, as compared to the year ended December 31, 2011. The increase in amortization of completed technology during the year ended December 31, 2012 was attributable primarily to $1.8 million increase in amortization related to the VelQuest Acquisition, the Aegis Acquisition and the Contur Acquisition, offset by a decrease in amortization of approximately $1.4 million related to the intangibles acquired in the Symyx Merger.

Operating Expenses



	For the Years Ended December 31
	2013	2012	2011	% Change 2013-2012		% Change 2012-2011
Product development	37,477	38,849	33,977	(4	)%	14	%
Sales and marketing	60,786	57,971	51,517	5	%	13	%
General and administrative	16,503	17,480	16,467	(6	)%	6	%
Business consolidation, restructuring and headquarter-relocation costs	15,477	7,803	7,775	98	%	—	%
Purchased intangible asset amortization	10,310	8,939	9,846	15	%	(9	)%

Comparison of the Years Ended December 31, 2013 and 2012

Product Development Expenses. Product development expenses for the year ended December 31, 2013 decreased to $37.5 million, or by 4%, as compared to the year ended December 31, 2012. The decrease in product development expenses during the year ended December 31, 2013 was primarily attributable to a decrease in personnel and related expenses of approximately $1.4 million as a result of the July 2013 Restructuring Plan, partially offset by the impact of higher headcount resulting primarily from the ChemSW Acquisition and the Qumas Acquisition, a decrease in overhead expense of approximately $0.4 million, partially offset by an increase in professional fees of approximately $0.4 million.

Sales and Marketing Expenses. Sales and marketing expenses for the year ended December 31, 2013 increased to $60.8 million, or by 5%, as compared to the year ended December 31, 2012. The increase in sales and marketing expenses during the year ended December 31, 2013 was primarily attributable to an increase in personnel and related expenses of approximately $1.5 million as a result of higher headcount resulting primarily from the Vialis Acquisition, the ChemSW Acquisition and the Qumas Acquisition, an increase in professional fees of $0.5 million and an increase in overhead expense of approximately $0.8 million.

General and Administrative Expenses. General and administrative expenses for the year ended December 31, 2013 decreased to $16.5 million, or by 6%, as compared to the year ended December 31, 2012. The decrease in general and administrative expenses during the year ended December 31, 2013 was primarily attributable to a decrease in personnel and related expenses as a result of the July 2013 Restructuring Plan and a decrease in incentive compensation.

Business Consolidation, Restructuring and Headquarter-Relocation Costs. Business consolidation, restructuring and headquarter-relocation costs for the year ended December 31, 2013 increased to $15.5 million. On July 26, 2013, we committed to a plan (the "July 2013 Restructuring Plan") for the restructuring of approximately 80 employees primarily in the U.S., or about 12% of our total workforce. Approximately 40 positions are expected to be filled in the future in different capacities or locations to rebalance the skillset of our employee base as part of this realignment. In connection with this plan, we expect to incur total charges of approximately $2.4 million through the second quarter of fiscal 2014 consisting of severance, retention and relocation costs.

As part of the July 2013 Restructuring Plan, we also committed to exit a portion of our facility in San Ramon, California by April 1, 2014. We are contractually obligated under this operating lease through 2015. In connection with the exit of the facility, we anticipate incurring facility closure costs between $1.2 million and $1.5 million through April 1, 2014. The restructuring of the facility involves three phases. During the fourth quarter of fiscal 2013, we reached the cease-use date for the first phase of the restructuring and expect to reach a cease-use date for the remaining two phased of the facility restructuring in the first quarter of fiscal 2014.

The increase in business consolidation, restructuring and headquarter-relocation costs for the year ended December 31, 2013 was primarily attributable to an increase in personnel and overhead related costs of $6.7 million related to employees who were notified that their employment with us was being terminated as a result of our restructuring activities including severance and normal compensation costs during transition periods from notification to termination, an increase in acquisition-related contingent compensation primarily due to the Vialis Acquisition and the ChemSW Acquisition of $1.8 million, an increase in costs associated with our headquarter relocation in July 2013 of approximately $2.0 million and a decrease in legal, litigation settlement and other professional costs attributable to the Acquisitions of $2.7 million primarily attributable to insurance proceeds we received related to the Borealis litigation settlement discussed in Note 15 of the notes to consolidated financial

statements. Our headquarter relocation costs include additional rent expense during the transition to the new facility of $0.9 million.

Note Receivable Impairment. As a result of indicators of impairment identified in the fourth quarter of 2013, we evaluated the recoverability of the Freeslate note receivable based on a discounted cash flow model and as a result of this analysis we established a reserve of $1.7 million through an impairment charge on the note receivable which is included in the consolidated statement of operations for the year ended December 31, 2013. Refer to Note 6 Fair Value for further discussion regarding the assumptions used in our impairment analysis.

Purchased Intangible Asset Amortization. Purchased intangible asset amortization for the year ended December 31, 2013 increased to $10.3 million, or 15%, as compared to the same period last year. The increase in purchased intangible asset amortization during both periods was attributable to an increase in intangible assets acquired in the Acquisitions and relates to the amortization of backlog, customer relationship and trademark intangible assets acquired in the Acquisitions.

Comparison of the Years Ended December 31, 2012 and 2011

Product Development Expenses. Product development expenses for the year ended December 31, 2012 increased to $38.8 million, or by 14%, as compared to the year ended December 31, 2011. The increase in product development expenses during the year ended December 31, 2012 was primarily attributable to an increase in personnel and related expenses of approximately $4.6 million as a result of higher headcount and an increase in professional fees of approximately $0.4 million, partially offset by a decrease in overhead expense of approximately $0.1 million.

Sales and Marketing Expenses. Sales and marketing expenses for the year ended December 31, 2012 increased to $58.0 million, or by 13%, as compared to the year ended December 31, 2011. The increase in sales and marketing expenses for the year ended December 31, 2012 was primarily attributable to an increase in personnel-related expenses of approximately $6.0 million and an increase in professional fees of approximately $0.8 million, partially offset by a decrease in overhead expense of approximately $0.4 million.

General and Administrative Expenses. General and administrative expenses for the year ended December 31, 2012 increased to $17.5 million, or by 6%, as compared to the year ended December 31, 2011. The increase in general and administrative expenses during the year ended December 31, 2012 was primarily attributable to an increase in personnel-related expenses of $1.3 million, partially offset by a decrease in overhead expense of approximately $0.3 million.

Business Consolidation, Restructuring and Headquarter-Relocation Costs. Business consolidation, restructuring and headquarter-relocation costs for the year ended December 31, 2012 increased to $7.8 million and consisted primarily of business consolidation costs related to recent acquisitions, including accounting, legal, litigation and costs incurred to integrate acquired companies, including consultant and employee-related costs incurred during integration and transition periods. We have classified all transaction and integration-related costs to business consolidation costs, transaction and restructuring costs, which for the year ended December 31, 2012 includes $1.0 million of acquisition-related contingent compensation and professional services, legal, litigation and other costs of $7.1 million directly related to our acquisitions and integrating them into our company, partially offset by a write-off of lease-related obligations of $0.4 million.

Purchased Intangible Asset Amortization. Purchased intangible asset amortization for the year ended December 31, 2012 decreased to $8.9 million, or 9%, as compared to the same period last year. The decrease in purchased intangible asset amortization during the year ended December 31, 2012 was attributable primarily to $1.2 million increase in amortization related to the VelQuest Acquisition, the Aegis Acquisition and the Contur Acquisition, offset by a decrease in amortization of approximately $2.1 million related to the intangibles acquired in the Symyx Merger.

Royalty and Other Income, net



	For the Years Ended December 31
	2013	2012	2011	% Change 2013-2012		% Change 2012-2011
Royalty and other income, net	6,356	8,870	1,740	(28	)%	410	%

Royalty and other income, net for the year ended December 31, 2013 decreased to $6.4 million, or 28%, as compared to the year ended December 31, 2012. Royalty and other income, net for the year ended December 31, 2012 increased to $8.9 million as compared to the year ended December 31, 2011.

Significant components of royalty and other income, net for the year ended December 31, 2013 included net royalty income of $6.0 million, interest income of $1.6 million and amortization of the discount on promissory notes receivable of $0.8 million, partially offset by foreign currency exchange loss of $0.5 million and amortization of purchased intangible assets of $1.6 million.

Significant components of royalty and other income, net for the year ended December 31, 2012 included net royalty revenue of $5.4 million, interest income of $2.3 million, amortization of the discount on promissory notes receivable of $0.9 million and net gain on the sale of real estate of $2.7 million, partially offset by a foreign currency exchange loss of $0.6 million, amortization of purchased intangible assets of $1.7 million and $0.3 million net loss from rental activities primarily related to the write-off of certain lease-related assets.

Significant components of royalty and other income, net for the year ended December 31, 2011 included royalty revenue of $6.8 million, interest income of $1.5 million, amortization of the discount on promissory notes receivable of $0.2 million, and a foreign currency exchange gain of $0.5 million, partially offset by a $4.3 million write-off of intangible assets in connection with the sale of intellectual property and related deferred gain on sale as described in detail in Note 5 to the consolidated financial statements included elsewhere in this Report, royalty expense of $0.6 million and amortization of purchased intangible assets of $2.4 million

Gain on Sale of Intellectual Property

Pursuant to the terms of the agreement between Symyx and Intermolecular, Inc. (“IM”), dated July 28, 2011 (the “IM Agreement”), we sold to IM certain patents relating to Symyx’s legacy high-throughput research business in consideration for a secured promissory note receivable in a principal amount equal to $27.3 million due in November 2013 (the “IM Note”). In connection with the sale of the intellectual property we wrote off intangible assets sold to IM with a net book value of $4.3 million in the fourth quarter of fiscal 2011 and, based on our assessment of the relevant revenue recognition guidance and other factors, we deferred recognition of the portion of the net gain equal to the fair value of the IM Note of $26.0 million. On May 31, 2013, IM paid off the IM Note in full pursuant the penalty-free pre-payment option. As a result, we recognized a $25.9 million gain on sale of intellectual property in the second quarter of fiscal 2013.

Net Gain on Sale of Cost Method Investment

Pursuant to the terms of the IM Agreement, we sold our equity interest in IM in their November 18, 2011 initial public offering (the “IPO”). Upon consummation of the IPO, we received proceeds of approximately $37.3 million, net of transaction and consulting costs and commissions of $2.4 million. The carrying value of our investment in IM prior to the IPO was $18.3 million. As a result, during the fourth quarter of fiscal 2011, we recognized a net gain of approximately $19.0 million on the sale of our equity investment in IM.

Income Tax Expense



	For the Years Ended December 31
	2013		2012	2011		% Change 2013-2012		% Change 2012-2011
Income Tax Expense (Benefit)	(1,496	)	218	(756	)	(786	)%	(129	)%

Comparison of the Years Ended December 31, 2013 and 2012

Income tax expense consists of provision for income taxes for federal and state income taxes in the U.S. and in certain foreign tax jurisdictions. Income tax benefit for the year ended December 31, 2013 was $1.5 million as compared to income tax expense of $0.2 million for the year ended December 31, 2012. The decrease in income tax expense during the year ended December 31, 2013 was primarily attributable to the release of valuation allowance of $3.6 million related to the Aegis Acquisition, offset by the receipt of cash related to the IM note on May 31, 2013 and consequently, recognition of the related gain on sale of intellectual property, and the change in earnings mix around the world.

Comparison of the Years Ended December 31, 2012 and 2011

Income tax expense increased to $0.2 million for the year ended December 31, 2012, as compared to income tax benefit of $0.8 million for the year ended December 31, 2011. Income tax expense consists of provision for income taxes for federal and state income taxes in the U.S. and income taxes in certain foreign tax jurisdictions. Income tax benefit related to U.S. jurisdictions was $0.7 million for the year ended December 31, 2012 compared to income tax expense of $0.4 million for the year ended December 31, 2011. The income tax benefit for the year ended December 31, 2012 resulted from a release in the

fourth quarter of 2012 of $2.2 million of liability for unrecognized tax benefits due to the expiration of the statute of limitations applicable to the 2007 tax year, offset by $1.5 million of income tax expense.

Income tax expense related to foreign jurisdictions was $0.9 million for the year ended December 31, 2012 compared to income tax benefit of $1.2 million for the year ended December 31, 2011, which resulted primarily from a valuation allowance release for one of our United Kingdom subsidiaries.

Liquidity and Capital Resources

We had cash, cash equivalents, marketable securities, and restricted cash of $66.9 million as of December 31, 2013, as compared to $115.6 million as of December 31, 2012, a decrease of $48.7 million. Of these amounts, $14.7 million and $16.1 million as of December 31, 2013 and December 31, 2012, respectively, were held by our foreign subsidiaries. If such funds are needed for our U.S. operations, the repatriation of cash balances from our foreign subsidiaries could result in the recognition and payment of U.S. income taxes. We generally invest our cash and cash equivalents in investment grade, highly liquid fixed income securities. Our marketable securities portfolio is denominated in U.S. dollars and consists of investment grade, highly liquid securities of various holdings including obligations of U.S. government sponsored enterprises, commercial paper, certificates of deposit, and corporate and municipal debt. Our primary objective for holding fixed income securities is to achieve an appropriate investment return consistent with preserving principal and managing risk.

The decrease in cash, cash equivalents, marketable securities and restricted cash during the year ended December 31, 2013 was primarily attributable to cash paid, net of cash acquired of $62.3 million from the Acquisitions completed in fiscal 2013, including $48.0 million of net cash paid for the Qumas Acquisition and $14.8 million of net cash paid for the ChemSW Acquisition offset by net cash acquired from the Vialis Acquisition of $0.5 million in 2013 as a result of an acquisition related deposit we made for the Vialis Acquisition in December 2012. The decrease in cash, cash equivalents, marketable securities and restricted cash during the year ended December 31, 2013 was also attributable to purchases of property and equipment of $11.5 million and repurchases of our common stock of $15.0 million, partially offset by cash from operations of $10.1 million, proceeds from the IM Note of $26.5 million and proceeds from the sale of common stock of $4.5 million, net of shares tendered for payment of withholding tax and $1.0 million of unfavorable effect of changes in exchange rates on cash and cash equivalents, primarily in Japan.

The following table sets forth a summary of our cash flows for the periods indicated (in thousands):



	For the Years Ended
	December 31, 2013			December 31, 2012

Net cash provided by operating activities	$	10,977		$	18,265
Net cash provided by (used) in investing activities	(34,331		)	(9,510		)
Net cash used in financing activities	(10,808		)	(5,355		)

Net cash provided by operating activities was $11.0 million for the year ended December 31, 2013, as compared to $18.3 million for the year ended December 31, 2012. Cash provided by operating activities for the year ended December 31, 2013 was primarily attributable to net income of $5.7 million, net cash outflow from changes in operating assets and liabilities of $7.2 million and non-cash charges of $41.9 million. These items were offset by the $25.9 million of gain on sale of intellectual property resulting from the collection of the IM note in May 2013, the proceeds of which are included in cash provided by investing activities discussed below and the release of valuation allowance of $3.6 million related to the Aegis Acquisition. Cash provided by operating activities for the year ended December 31, 2012 was primarily attributable to net cash inflow from changes in operating assets and liabilities of $0.9 million and non-cash charges of $27.8 million, offset by net loss of $10.4 million. The non-cash charges in both periods were primarily related to depreciation, amortization, stock-based compensation, contingent compensation expense, amortization of net premium on marketable securities and discount on promissory notes receivable, deferred taxes and other non-cash adjustments. The non-cash charges for the year ended December 31, 2013 also included note receivable impairment charge and a cease-use charge related to our restructuring activities.

Net cash used in investing activities was $34.3 million for the year ended December 31, 2013, as compared to net cash used in investing activities of $9.5 million for the year ended December 31, 2012. Significant components of cash flows from investing activities for the year ended December 31, 2013 included cash paid, net of cash acquired of $62.3 million from the Acquisitions completed in 2013, including $48.0 million of net cash paid for the Qumas Acquisition, and $14.8 million of net cash paid for the ChemSW Acquisition, offset by net cash acquired from the Vialis Acquisition of $0.5 million as a result of an acquisition related deposit we made for the Vialis Acquisition in December 2012. Other significant components of cash flows from investing activities for the year ended December 31, 2013 included proceeds from the IM Note of $26.5 million and proceeds from maturities of marketable securities of approximately $42.1 million, partially offset by purchases of marketable securities of approximately $32.4 million and net purchases of property and equipment of $11.5 million.

Significant components of cash flows from investing activities for the year ended December 31, 2012 included $35.2 million in cash paid for the acquisition of the HEOS platform and the Aegis Acquisition, $5.5 million paid for an acquisition-

related deposit in the Vialis Acquisition, net purchases of property and equipment of $6.3 million and purchases of marketable securities of approximately $51.0 million, partially offset by proceeds from maturities of marketable securities of approximately $80.6 million, net proceeds from the sale of real estate of $6.8 million and payments on promissory notes receivable of $0.8 million.

Net cash used in financing activities was $10.8 million for the year ended December 31, 2013, as compared to $5.4 million for the year ended December 31, 2012. Significant components of cash used in financing activities for the year ended December 31, 2013 included repurchases of our common stock of $15.0 million and payment of contingent consideration liabilities related to the Contur Acquisition of $0.25 million, partially offset by $4.5 million of proceeds from the issuance of common stock under our equity incentive plans, reduced by payments made to taxing authorities on behalf of our employees when tendering stock to us for settlement of minimum income tax liability upon vesting of restricted stock units (“RSUs”). Significant components of cash used in financing activities for the year ended December 31, 2012 included repurchases of our common stock of $11.3 million and payment of contingent consideration liabilities related to the Contur Acquisition of $0.25 million, partially offset by $6.2 million of proceeds from the issuance of common stock under our equity incentive plans, reduced by payments made to taxing authorities on behalf of our employees when tendering stock to us for settlement of minimum income tax liability upon vesting of RSUs.

We have funded our activities to date primarily through the sales of software licenses and related services and the issuance of equity securities.

We anticipate that our capital requirements may increase in future periods as a result of seasonal sales trends, additional product development activities and infrastructure investments. Our capital requirements may also increase in future periods as we seek to expand our technology platform through investments, licensing arrangements, technology alliances or acquisitions.

We anticipate that our existing capital resources will be adequate to fund our operations for at least the next twelve months. However, there can be no assurance that changes will not occur that would consume our available capital resources before that time. Our capital requirements depend on numerous factors, including our ability to continue to generate software sales, the purchase of additional capital equipment and acquisitions of other businesses or technologies. There can be no assurance that additional funding, if necessary, will be available to us on favorable terms, if at all. Our forecast for the period of time through which our financial resources will be adequate to support our operations is forward-looking information, and actual results could vary.

Contractual Obligations

Our long-term contractual obligations as of December 31, 2013 are as follows (in thousands):



			Payment Due by Period
Contractual Obligations	Total		Less than 1 Year		1 to 3 Years		3 to 5 Years		After 5 Years
Operating leases, net of subleases	$	34,943	$	5,872	$	8,432	$	6,403	$	14,236
Minimum royalty payments(1)	$	7,636	1,105		2,343		2,533		1,655
Total	$	42,579	$	6,977	$	10,775	$	8,936	$	15,891


(1)	Includes indefinite-lived contractual minimum royalty payments due in the ten fiscal years following December 31, 2013.

We are obligated to pay royalties for licenses to enhance and market certain software used in connection with our product offerings. In addition to the contractual minimum royalties included in the table above, we have several royalty agreements that are long term or perpetual in nature with royalty obligations that are generally based on a percentage of revenues derived from certain software license sales and associated sales of PCS. The royalty agreements require quarterly payments and generally do not limit the maximum royalties owed. We incurred royalty related expenses of $5.3 million, $5.5 million and $5.8 million for the years ended December 31, 2013, 2012 and 2011, respectively.

On April 30, 2004, in connection with the spin-off of PDD, the landlords of our New Jersey facilities, which were used by our PDD operations, consented to the assignment of the leases to PDD. Despite the assignment, the landlords required us to guarantee the remaining lease obligations, which totaled approximately $6.2 million as of December 31, 2013 In accordance with ASC Topic 460, Guarantor’s Accounting and Disclosure Requirements for Guarantees, Including Indirect Guarantees of Indebtedness of Others, we recognized a liability and corresponding charge to stockholders’ equity for the probability-weighted fair market value of the guarantee. Changes to the fair market value of the liability are recognized in stockholders’ equity. The

liability for our guarantee of the lease obligation was $0.1 million and $0.2 million at December 31, 2013 and 2012, respectively.

Off-Balance Sheet Arrangements and Related Party Transactions

As of December 31, 2013 we did not have any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. As such, we are not materially exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in such relationships.

We do not have relationships or transactions with persons or entities that derive benefits from their non-independent relationship with us or our related parties.

Recently Issued Accounting Standards

See Note 1 to our audited consolidated financial statements included elsewhere in this Report for recently issued accounting standards, including the expected dates of adoption and expected impact on our consolidated financial statements upon adoption.

Common Stock Repurchases

Our Board of Directors from time to time approves common stock repurchase programs authorizing management to repurchase shares of our common stock in open market transactions in accordance with Rule 10b-18 of the Exchange Act. We repurchase shares primarily to offset dilution caused by ongoing stock issuances from existing equity compensation plans and to improve stockholders’ returns. Repurchased shares are recorded as treasury stock upon repurchase and are subsequently retired.

On August 3, 2011 and February 29, 2012, our board of directors authorized the Company to commit up to $8.0 million and $2.0 million, respectively, for an aggregate of $10.0 million, for the repurchase of the Company's common stock during fiscal 2012 pursuant to a program to be executed in accordance with a Rule 10b5-1 trading plan. On March 14, 2012, we entered into a stock repurchase plan (the “2012 Repurchase Plan”) in accordance with Rule 10b5-1 of Exchange Act. Pursuant to the 2012 Repurchase Plan, and subject to the conditions set forth therein and the provisions of Rule 10b-18 of the Exchange Act, we instructed the broker to purchase for our account up to $10.0 million worth of our common stock by December 31, 2012.

On December 13, 2012, we entered into a stock repurchase plan (the “2013 Repurchase Plan”) in accordance with Rule 10b5-1 of the Exchange Act. Pursuant to the Repurchase Plan, and subject to the conditions set forth therein and the provisions of Rule 10b-18 of the Exchange Act, we instructed our broker to purchase for our account up to $15.0 million worth of our common stock by December 31, 2013.

We have made cumulative repurchases of 4,255,153 shares, at a cost of approximately $36.3 million (including commissions), since we began our stock repurchase program in November 2010. All repurchased shares of common stock have been retired.

The following table provides a summary of the repurchase activity for the periods indicated under our stock repurchase program:



	For the Years Ended
	December 31, 2013		December 31, 2012		December 31, 2011
	(in thousands, except per share price)
Shares repurchased	1,651		1,373		877
Average purchase price	$	9.12	$	8.22	$	7.98
Aggregate purchase price	$	15,047	$	11,290	$	7,000



Item 7A.	Quantitative and Qualitative Disclosures About Market Risk

In addition to our U.S. operations, we have operations in Europe and the Asia/Pacific region. As a result, our financial position, results of operations and cash flows can be affected by fluctuations in foreign currency exchange rates, particularly fluctuations in the pound sterling, euro and yen exchange rates. Many of our reporting entities conduct a portion of their business in currencies other than the entity’s functional currency. These transactions give rise to receivables and payables that are denominated in currencies other than the entity’s functional currency. The value of these receivables and payables is subject to changes in exchange rates because the receivables and payables may become worth more or less than they were worth at the time we entered into the transaction due to changes in currency exchange rates. The majority of our software license agreements are denominated in U.S. dollars. Both realized and unrealized gains or losses on the value of these receivables and payables, along with the settlement of certain intercompany transactions, are included in the determination of net income.

To mitigate our risk from foreign currency fluctuations, we launched a foreign currency hedging program in December 2011 whereby we will periodically enter into currency derivative contracts, principally forward contracts with short term maturities. Our intent is to offset gains and losses that occur from the underlying exposure with gains and losses on the derivative contracts used to offset them. We do not hold or purchase any foreign currency contracts for trading or speculative purposes and we do not designate these forward contracts or swaps as hedging instruments. Accordingly, we report the fair value of these contracts in the consolidated balance sheet with changes in fair value recorded in the consolidated statements of operations. The fair value of foreign currency contracts is estimated based on the prevailing exchange rates of the various hedged currencies as of the end of the period.

Our investment portfolio is maintained in accordance with our investment policy that defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. None of our investments are held for trading or speculative purposes. The fair value of our cash equivalents and marketable securities is subject to change as a result of changes in market interest rates and investment risk related to the issuers’ credit worthiness. We do not utilize financial contracts to manage our exposure in our investment portfolio to changes in interest rates. A hypothetical 100 basis point increase or decrease in market interest rates would not have a material impact on the fair value of our cash equivalents and marketable securities due to the relatively short maturities of these investments. While changes in interest rates may affect the fair value of our investment portfolio, any gains or losses will not be recognized in our results of operations until the investment is sold or if the reduction in fair value was determined to be an other-than-temporary impairment.



Item 8.	Financial Statements and Supplementary Data

Report of Independent Registered Public Accounting Firm

The Board of Directors and Stockholders

Accelrys, Inc.

We have audited the accompanying consolidated balance sheets of Accelrys, Inc. as of December 31, 2013 and 2012, and the related consolidated statements of operations, comprehensive income (loss), stockholders’ equity, and cash flows for each of the three years in the period ended December 31, 2013. Our audits also included the financial statement schedule listed in the index at Item 15(a)(2). These financial statements and schedule are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements and schedule based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the consolidated financial position of Accelrys, Inc. at December 31, 2013 and 2012, and the consolidated results of its operations and its cash flows for each of the three years in the period ended December 31, 2013, in conformity with U.S. generally accepted accounting principles. Also, in our opinion, the related financial statement schedule, when considered in relation to the basic financial statements taken as a whole, presents fairly in all material respects the information set forth therein.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), Accelrys, Inc.’s internal control over financial reporting as of December 31, 2013, based on the criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (1992 Framework) and our report dated March 7, 2014 expressed an unqualified opinion thereon.

/s/ Ernst & Young LLP

San Diego, California

March 7, 2014

Accelrys, Inc.

Consolidated Balance Sheets

(In thousands)



	December 31, 2013			December 31, 2012

Assets
Current assets:
Cash and cash equivalents	$	37,628		$	72,747
Restricted cash	—			3,227
Marketable securities	25,880			26,851
Trade receivables, net of allowance for doubtful accounts of $143 as of December 31, 2013 and December 31, 2012	45,510			47,196
Promissory note receivable	1,000			25,895
Prepaid expenses, deferred tax assets and other current assets	11,696			10,492
Total current assets	121,714			186,408
Marketable securities, net of current portion	2,879			12,548
Restricted cash, net of current portion	516			273
Property and equipment, net	18,449			10,888
Goodwill	158,507			123,670
Purchased intangible assets, net	68,671			53,223
Promissory notes receivable, net of current portion	6,393			8,901
Other assets	15,437			9,931
Total assets	$	392,566		$	405,842
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$	2,481		$	3,279
Accrued liabilities	16,117			19,760
Accrued compensation and benefits	12,078			14,514
Current portion of accrued restructuring charges	1,463			324
Deferred gain on sale of intellectual property	—			25,895
Current portion of deferred revenue	82,275			86,340
Total current liabilities	114,414			150,112
Deferred revenue, net of current portion	3,342			2,811
Accrued income tax	19,943			8,710
Accrued restructuring charges, net of current portion	359			367
Lease-related liabilities, net of current portion	6,049			1,021
Stockholders’ equity:
Preferred stock, $.0001 par value; 2,000 shares authorized; no shares issued and outstanding	—			—
Common stock, $.0001 par value; 100,000 shares authorized; 55,713 and 55,879 shares issued and outstanding at December 31 2013 and December 31, 2012, respectively	6			6
Additional paid-in capital	493,509			480,001
Lease guarantee	(147		)	(210		)
Accumulated deficit	(247,597		)	(238,240		)
Accumulated other comprehensive income	2,688			1,264
Total stockholders’ equity	248,459			242,821
Total liabilities and stockholders’ equity	$	392,566		$	405,842

See accompanying notes to these consolidated financial statements.

Accelrys, Inc.

Consolidated Statements of Operations

(In thousands, except per share amounts)



	For the Years Ended
	December 31, 2013			December 31, 2012			December 31, 2011
Revenue:
License and subscription revenue	$	86,393		$	89,440		$	79,425
Maintenance on perpetual licenses	40,196			38,254			34,862
Content	9,864			12,485			16,838
Professional services and other	32,073			22,347			13,214
Total revenue	168,526			162,526			144,339
Cost of revenue:
Cost of revenue	44,791			41,695			36,065
Amortization of completed technology	9,576			8,843			8,393
Total cost of revenue	54,367			50,538			44,458
Gross profit	114,159			111,988			99,881
Operating expenses:
Product development	37,477			38,849			33,977
Sales and marketing	60,786			57,971			51,517
General and administrative	16,503			17,480			16,467
Business consolidation, transaction and headquarter-relocation costs	15,477			7,803			7,775
Note Receivable Impairment	1,663			—			—
Purchased intangible asset amortization	10,310			8,939			9,846
Total operating expenses	142,216			131,042			119,582
Operating loss	(28,057		)	(19,054		)	(19,701		)
Net gain on sale of intellectual property	25,895			—			—
Net gain on sale of cost method investment	—			—			18,970
Royalty and other income, net	6,356			8,870			1,740
Income (loss) before income taxes	4,194			(10,184		)	1,009
Income tax expense (benefit)	(1,496		)	218			(756		)
Net income (loss)	$	5,690		$	(10,402	)	$	1,765

Net income (loss) per share amounts:
Basic	$	0.10		$	(0.19	)	$	0.03
Diluted	$	0.10		$	(0.19	)	$	0.03
Weighted average shares used to compute net income (loss) per share:
Basic	55,686			55,696			55,489
Diluted	57,061			55,696			56,037

See accompanying notes to these consolidated financial statements.

Accelrys, Inc.

Consolidated Statements of Comprehensive Income (Loss)

(In thousands)



	For the Years Ended
	December 31, 2013			December 31, 2012			December 31, 2011

Net income (loss)	$	5,690		$	(10,402	)	$	1,765
Other comprehensive income (loss):
Foreign currency translation adjustment	1,477			1,479			(1,726		)
Unrealized gain (loss) on marketable securities, net of tax	(53		)	(13		)	118
Total other comprehensive income (loss)	1,424			1,466			(1,608		)
Comprehensive income (loss)	$	7,114		$	(8,936	)	$	157

See accompanying notes to these consolidated financial statements.

Accelrys, Inc.

Consolidated Statements of Stockholders’ Equity

(In thousands)



	Common Stock				Additional Paid-In Capital		Lease Guarantee			Treasury Stock					Accumulated Deficit			Accumulated Other Comprehensive Income (Loss)			Total Stockholders’ Equity
	Shares		Amount		Additional Paid-In Capital		Lease Guarantee			Shares		Amount			Accumulated Deficit			Accumulated Other Comprehensive Income (Loss)			Total Stockholders’ Equity
Balance at December 31, 2010	56,733		$	6	$	457,883	$	(336	)	998		$	(11,340	)	$	(199,973	)	$	1,406		$	247,646
Net income	—		—		—		—			—		—			1,765			—			1,765
Other comprehensive loss	—		—		—		—			—		—			—			(1,608		)	(1,608		)
Change in value of lease guarantee	—		—		—		63			—		—			—			—			63
Stock-based compensation expense	—		—		5,572		—			—		—			—			—			5,572
Excess tax benefit from exercise of stock options	—		—		169		—			—		—			—			—			169
Repurchase of common stock	—		—		—		—			877		(7,000		)	—			—			(7,000		)
Issuance of common stock upon exercise of stock options and under employee stock purchase plan, net of shares tendered	855		—		2,077		—			—		—			—			—			2,077
Balance at December 31, 2011	57,588		$	6	$	465,701	$	(273	)	1,875		$	(18,340	)	$	(198,208	)	$	(202	)	$	248,684
Net loss	—		—		—		—			—		—			(10,402		)	—			(10,402		)
Other comprehensive income	—		—		—		—			—		—			—			1,466			1,466
Change in value of lease guarantee	—		—		—		63			—		—			—			—			63
Stock-based compensation expense	—		—		8,115		—			—		—			—			—			8,115
Excess tax benefit from exercise of stock options	—		—		19		—			—		—			—			—			19
Repurchase of common stock	—		—		—		—			1,374		(11,290		)	—			—			(11,290		)
Retirement of treasury stock	(3,249	)	—		—		—			(3,249	)	29,630			(29,630		)	—			—
Issuance of common stock upon exercise of stock options and under employee stock purchase plan, net of shares tendered	1,540		—		6,166		—			—		—			—			—			6,166
Balance at December 31, 2012	55,879		$	6	$	480,001	$	(210	)	—		$	—		$	(238,240	)	$	1,264		$	242,821
Net income	—		—		—		—			—		—			5,690			—			5,690
Other comprehensive income	—		—		—		—			—		—			—			1,424			1,424
Change in value of lease guarantee	—		—		—		63			—		—			—			—			63
Stock-based compensation expense	—		—		9,019		—			—		—			—			—			9,019
Excess tax benefit from exercise of stock options	—		—		—		—			—		—			—			—			—
Repurchase of common stock	—		—		—		—			1,651		(15,047		)	—			—			(15,047		)
Retirement of treasury stock	(1,651	)	—		—		—			(1,651	)	15,047			(15,047		)	—			—
Issuance of common stock upon exercise of stock options and under employee stock purchase plan, net of shares tendered	1,485		—		4,489		—			—		—			—			—			4,489
Balance at December 31, 2013	55,713		$	6	$	493,509	$	(147	)	—		$	—		$	(247,597	)	$	2,688		$	248,459

Accelrys, Inc.

Consolidated Statements of Cash Flows

(In thousands)



	For the Years Ended
	December 31, 2013			December 31, 2012			December 31, 2011
Cash flows from operating activities:
Net income (loss)	$	5,690		$	(10,402	)	$	1,765
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation	4,183			3,325			3,800
Amortization	21,643			19,889			21,016
Gain on sale of real estate	—			(2,744		)	—
Share-based compensation	9,019			8,115			5,572
Note receivable impairment	1,663			—			—
Cease use loss	744			—			—
Change in fair value of contingent consideration liabilities	9			78			78
Contingent compensation expense	2,826			897			847
Amortization of premium on marketable debt securities	924			1,244			1,739
Amortization of discount on promissory notes receivable	(762		)	(892		)	(155		)
Release of valuation allowance against deferred tax assets	(3,566		)	(334		)	(1,120		)
Deferred income taxes	1,004			(1,100		)	(2,105		)
Excess tax benefit from exercise of stock options	—			(19		)	(169		)
Net gain on sale of cost method investment	—			—			(18,970		)
Write-off of intangible asset in connection with the sale of intellectual property	—			—			4,303
Gain on sale of intellectual property	(25,895		)	—			—
Unrealized losses on foreign currency forward contracts	(133		)	(18		)	117
Other	826			(685		)	(390		)
Changes in operating assets and liabilities:
Trade receivables	7,586			(5,781		)	(6,304		)
Prepaid expense and other current assets	(1,310		)	1,769			1,578
Other assets	152			82			1,444
Accounts payable	(1,483		)	(437		)	(802		)
Accrued liabilities, compensation and benefits	(7,972		)	1,469			(2,579		)
Deferred revenue	(4,171		)	3,791			14,070
Net cash provided by operating activities	10,977			18,247			23,735
Cash flows from investing activities:
Cash paid for acquisitions, net of cash acquired	(67,453		)	(35,229		)	(44,564		)
Deposit for business acquisitions	5,202			(5,476		)	—
Acquisition-related prepaid contingent compensation	—			—			(2,000		)
Purchases of property and equipment, net	(11,486		)	(6,332		)	(3,908		)
Net proceeds from sale of real estate	—			6,800			—
Purchases of marketable securities	(32,436		)	(51,031		)	(104,110		)
Proceeds from maturities and sales of marketable securities	42,114			80,613			81,505
Net proceeds from sale of cost method investment	—			—			37,293
Proceeds from promissory notes receivable	26,502			816			—
Net decrease in restricted cash	3,226			329			275



Net cash provided by (used in) investing activities	(34,331		)	(9,510		)	(35,509		)

Cash flows from financing activities:
Payment of contingent consideration liabilities	(250		)	(250		)	—
Proceeds from issuance of common stock	6,535			7,356			2,991
Common stock tendered for payment of withholding taxes	(2,046		)	(1,190		)	(914		)
Excess tax benefit from exercise of stock options	—			19			169
Repurchases of common stock	(15,047		)	(11,290		)	(7,000		)
Net cash (used in) provided by financing activities	(10,808		)	(5,355		)	(4,754		)
Effect of changes in exchange rates on cash and cash equivalents	(957		)	(245		)	(178		)
Increase (decrease) in cash and cash equivalents	(35,119		)	3,137			(16,706		)
Cash and cash equivalents at beginning of the year	72,747			69,610			86,316
Cash and cash equivalents at end of the year	$	37,628		$	72,747		$	69,610
Supplemental cash flow information:
Cash (received) paid during the year for income taxes, net of refunds	2,251			$	2,690		$	(1,181	)
Non-cash investing and financing activities:
Note receivable received in sale of intellectual property	$	—		$	—		$	25,974
Deferred gain on sale of intellectual property

ACCELRYS, INC. 10-K